#  @DeepSouthDoctor Keith Abrams Keith Abrams posts on X about bullish, $urgn, $tcmd, $hrmy the most. They currently have [-----] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours. ### Engagements: [-----] [#](/creator/twitter::1713609026/interactions)  - [--] Week [-----] +424% - [--] Month [------] +40% - [--] Months [-------] +34% - [--] Year [-------] +48% ### Mentions: [--] [#](/creator/twitter::1713609026/posts_active)  - [--] Month [--] +55% - [--] Months [---] +56% - [--] Year [---] +92% ### Followers: [-----] [#](/creator/twitter::1713609026/followers)  - [--] Week [-----] no change - [--] Month [-----] +1.30% - [--] Months [-----] +6.60% - [--] Year [-----] +14% ### CreatorRank: [---------] [#](/creator/twitter::1713609026/influencer_rank)  ### Social Influence **Social category influence** [finance](/list/finance) [stocks](/list/stocks) [cryptocurrencies](/list/cryptocurrencies) [technology brands](/list/technology-brands) [countries](/list/countries) [social networks](/list/social-networks) [currencies](/list/currencies) **Social topic influence** [bullish](/topic/bullish), [$urgn](/topic/$urgn) #4, [$tcmd](/topic/$tcmd) #1, [$hrmy](/topic/$hrmy) #1, [$vktx](/topic/$vktx), [$crvs](/topic/$crvs) #18, [longterm](/topic/longterm), [data](/topic/data), [$abeo](/topic/$abeo) #2, [$rzlt](/topic/$rzlt) **Top accounts mentioned or mentioned by** [@jfais20](/creator/undefined) [@semodough](/creator/undefined) [@avidresearch](/creator/undefined) [@monacobiotech](/creator/undefined) [@bokhzam](/creator/undefined) [@blasebio](/creator/undefined) [@buylowersellhih](/creator/undefined) [@chrisolin](/creator/undefined) [@berlinergy](/creator/undefined) [@andreagtc](/creator/undefined) [@mbbiotech](/creator/undefined) [@aamortazavi](/creator/undefined) [@jamesekrause](/creator/undefined) [@bradloncar](/creator/undefined) [@mathcoredad](/creator/undefined) [@oldgraperx](/creator/undefined) [@stockkhoj](/creator/undefined) [@shoshinvalue](/creator/undefined) [@jnap5c](/creator/undefined) [@sharkbiotech](/creator/undefined) **Top assets mentioned** [Harmony Biosciences Holdings, Inc. (HRMY)](/topic/$hrmy) [Viking Therapeutics, Inc (VKTX)](/topic/$vktx) [Prothena Corporation plc Ordinary Shares (PRTA)](/topic/$prta) [Arrowhead Research Corporation (ARWR)](/topic/$arwr) [Iovance Biotherapeutics, Inc. Common Stock (IOVA)](/topic/$iova) [Vir Biotechnology, Inc. Common Stock (VIR)](/topic/$vir) [Rainmaker Games (RAIN)](/topic/$rain) [Soleno Therapeutics, Inc. Common Stock (SLNO)](/topic/$slno) [IDEAYA Biosciences, Inc. Common Stock (IDYA)](/topic/$idya) [Axsome Therapeutics, Inc (AXSM)](/topic/$axsm) [Celcuity Inc. Common Stock (CELC)](/topic/$celc) [Structure Therapeutics Inc. (GPCR)](/topic/$gpcr) [Protagonist Therapeutics, Inc (PTGX)](/topic/$ptgx) [Taraxa (TARA)](/topic/$tara) [Vera Therapeutics, Inc. (VERA)](/topic/$vera) [Kymera Therapeutics, Inc. (KYMR)](/topic/$kymr) [Madrigal Pharmaceuticals, Inc. Common Stock (MDGL)](/topic/$mdgl) [Apellis Pharmaceuticals, Inc. Common Stock (APLS)](/topic/$apls) [Ocular Therapeutix, Inc. (OCUL)](/topic/$ocul) [Mirum Pharmaceuticals, Inc. Common Stock (MIRM)](/topic/$mirm) [Seagen Inc (SGEN)](/topic/$sgen) [Day One Biopharmaceuticals, Inc. (DAWN)](/topic/$dawn) [Inari Medical, Inc. (NARI)](/topic/$nari) [Mineralys Therapeutics, Inc. (MLYS)](/topic/$mlys) [Kyverna Therapeutics, Inc. (KYTX)](/topic/$kytx) [Agios Pharmaceuticals, Inc. (AGIO)](/topic/$agio) [Arcutis Biotherapeutics, Inc. (ARQT)](/topic/$arqt) [LianBio (LIAN)](/topic/$lian) [LYRA (LYRA)](/topic/$lyra) [Cullinan Management, Inc. (CGEM)](/topic/$cgem) [Xenon Pharmaceuticals Inc (XENE)](/topic/$xene) [TG Therapeutics, Inc. (TGTX)](/topic/$tgtx) ### Top Social Posts Top posts by engagements in the last [--] hours "$MLYS: That's what I wanted to see Mineralys Therapeutics Announces Positive Topline Results from Phase [--] Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria $MLYS: Re-bought full position ahead of imminent Ph2 hypertension/CKD readout. Am thinking data should be positive building on prior Ph3 success. While not my rationale for buying I do think company is a plausible takeout candidate. $MLYS: Re-bought full position ahead of imminent Ph2 hypertension/CKD readout. Am thinking data should be positive building on prior Ph3 success. While not" [X Link](https://x.com/DeepSouthDoctor/status/1934963979010351322) 2025-06-17T13:18Z [----] followers, [----] engagements "$MLYS - Bought full position $32. Company filed YE - earlier than previously advertised - for best-in-class hypertension drug awaiting Ph2 data this Q in 2nd indication. Plenty of cash over 30% off of 52-week highs" [X Link](https://x.com/anyuser/status/2013979897765769503) 2026-01-21T14:20Z [----] followers, [----] engagements "$ESPR - sold entire position for negligible loss. I've run out of patience was unhappy with both size of quarterly loss as well as rate of accelerated sales (and eventual peak sales). You know you're in trouble when ER doesn't mention net product sales in 1st paragraph" [X Link](https://x.com/DeepSouthDoctor/status/1854566474892857447) 2024-11-07T16:47Z [----] followers, [----] engagements "Biotech giveth ($CADL $CMX) and taketh ($CRVO) away this week. Crazy week for my portfolio" [X Link](https://x.com/DeepSouthDoctor/status/1866852187097436168) 2024-12-11T14:27Z [----] followers, [---] engagements "@RichardTip17589 No thoughts have never followed them. Will take a quick look though thanks for the name" [X Link](https://x.com/DeepSouthDoctor/status/1953180868635156989) 2025-08-06T19:46Z [----] followers, [---] engagements "$BCRX: Read the CC transcript re: $ATXS deal. If Ph3 LAI drug is approvable (data Q127) I like the deal. Company est. [----] $1B cash balance $1B+ revenue (going to $1.8B in 2033). Early pipeline and possible add'l future BD a potential bonus. All in all it's a solid l-t buy" [X Link](https://x.com/DeepSouthDoctor/status/1978443239263801548) 2025-10-15T12:50Z [----] followers, [----] engagements "$SLNO - Has handily beaten analyst estimates in all [--] Qs since Vykat launch in PWS Q225. Seemingly clearly on path for $1B+ in sales. Company bought back stock at higher levels profitable has $500m cash as of YE for possible acquisitions. Story seems increasingly bullish" [X Link](https://x.com/DeepSouthDoctor/status/2010704575599092174) 2026-01-12T13:25Z [----] followers, [----] engagements "$SLNO - for all of the progress below stock trading near 52-week lows at $43 - and last secondary in July [----] went for $85. Seems like plenty of room to run not to mention potential for a "bolt-on acquisition" that would be immediately accretive to earnings for $SLNO - Has handily beaten analyst estimates in all [--] Qs since Vykat launch in PWS Q225. Seemingly clearly on path for $1B+ in sales. Company bought back stock at higher levels profitable has $500m cash as of YE for possible acquisitions. Story seems increasingly bullish. $SLNO - Has handily beaten analyst estimates in all [--] Qs since" [X Link](https://x.com/DeepSouthDoctor/status/2010706277031133352) 2026-01-12T13:31Z [----] followers, [----] engagements "1H YTD= + 32% Top Winners: $CMRX $ATYR $VERA $RZLT $RIGL $RCKT $ABEO Top Losers: $PRTA $CRVO $LRMR $TCMD" [X Link](https://x.com/DeepSouthDoctor/status/1940035158284943461) 2025-07-01T13:10Z [----] followers, [----] engagements "$AVBP - sold for a 4% loss. Upon re-reviewing the company am a little less bullish on Q126 Ph3 data and I simply like something else better" [X Link](https://x.com/DeepSouthDoctor/status/1965405528814924219) 2025-09-09T13:22Z [----] followers, [----] engagements "One potential edge amateurs (like me) can have in biotech is finding unfollowed companies - then having the courage of your convictions. Most of my biggest wins past [--] months have been made that way (e.g. $CMRX $ETON $RZLT $TCMD $XERS) even though I sold some too early" [X Link](https://x.com/DeepSouthDoctor/status/1985711128048254988) 2025-11-04T14:10Z [----] followers, [----] engagements "$ARQT - for a commercialization stage SMID-cap bio they are by far the most "expensive" via the EV/prod revenue screen - [---] based on [----] estimates. There is a difference between a great company and its valuation. Congrats to those who enjoyed the ascent but . . " [X Link](https://x.com/DeepSouthDoctor/status/1992989749179724129) 2025-11-24T16:12Z [----] followers, [----] engagements "Portfolio Update/Current Positions in order of size: $TCMD $RZLT $IDYA $QNCE $URGN $TECX $KYTX $BCRX $AGIO Don't anticipate making any changes this month (unless a stock craters)" [X Link](https://x.com/DeepSouthDoctor/status/1996947669235691657) 2025-12-05T14:20Z [----] followers, [----] engagements "$KYMR - That was predictable. They should raise at this valuation. Will be interested in the offering price. https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-announces-proposed-public-offering-2 $KYMR - I'll be very surprised if they don't raise in the next [--] hours. They should b/c I think their valuation is awfully high. https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-announces-proposed-public-offering-2 $KYMR - I'll be very surprised if they don't raise in the next [--] hours. They should b/c I think their valuation" [X Link](https://x.com/DeepSouthDoctor/status/1998137615045058763) 2025-12-08T21:08Z [----] followers, [----] engagements "$TCMD keeps grinding higher sets new 52-week high today in sluggish market. Nothing sexy just an excellent growth story. My #1 position due to outsized gains (basis $10). $TCMD - Love that after initial profit-taking this morning stock con't to move up adding to recent impressive gains. [----] analyst consensus earnings estimates have risen. Really liked what I heard on the CC. Now fighting with $RZLT as a co-#1 position among my holdings. $TCMD - Love that after initial profit-taking this morning stock con't to move up adding to recent impressive gains. [----] analyst consensus earnings" [X Link](https://x.com/DeepSouthDoctor/status/1998783576267997389) 2025-12-10T15:55Z [----] followers, [----] engagements "@jfais20 @Kapstahoon Doing initial DD on $AARD. What red flags are you seeing/most concerned about" [X Link](https://x.com/DeepSouthDoctor/status/1999559093439111228) 2025-12-12T19:16Z [----] followers, [---] engagements "2025 performance was +77.5% but still made lots of mistakes. Big Wins: $CMRX $TCMD $URGN $QNCX $IDYA $ATYR Big Losses: $PRTA $VYNE $CRVO Biggest Regrets: $RZLT (not selling more pre-data) $CELC (selling all pre-data) $NKTR (not buying at lows) $ARWR (lack of patience)" [X Link](https://x.com/DeepSouthDoctor/status/2007093270602711159) 2026-01-02T14:15Z [----] followers, [----] engagements "Current positions by size: $TCMD $TECX $IOVA $URGN $VIR $AVBP $CRVS $GUTS Sold $QNCX $KYTX $ABEO for sizable s-t profits. $GUTS - like their data more due Q1/Q2/Q3. $AVBP - re-bought on weakness Ph3 data due Q1. $VIR - added more love the r/r. Ph1b data this month" [X Link](https://x.com/DeepSouthDoctor/status/2008907727137915142) 2026-01-07T14:25Z [----] followers, [----] engagements "$SPRB - bought at $77. Like the non-dilutive financing and I think the stock moves upward if/when they file their NDA this Q and more so if/when accepted by FDA. Company has BTD and is eligible for a PRV which is worth 1.5x current market cap" [X Link](https://x.com/DeepSouthDoctor/status/2009298717724000588) 2026-01-08T16:18Z [----] followers, [----] engagements "Bought $XENE $41. Stock price got way ahead of itself 4-5 years ago after stellar Ph2b data but now couldn't be more bullish about upcoming Ph3 readout (in March) that is likely a best-in-class drug for a large TAM. Would expect "the next leg up" after positive results" [X Link](https://x.com/anyuser/status/2011466638244114827) 2026-01-14T15:53Z [----] followers, [----] engagements "@jfais20 Per your "cage match" thinking there are several other commercial-stage bios that I think are far "cheaper"/ represent better value than $URGN - short list includes: $ABEO $BCRX $HRMY $IOVA $KURA $PLX $TCMD" [X Link](https://x.com/DeepSouthDoctor/status/2011589271908663721) 2026-01-15T00:00Z [----] followers, [----] engagements "@avidresearch Atopic Derm is becoming more crowded in general (e.g. $CLDX $KYMR). No sense in me speculating (any more) about how $CRVS data stacks up - we'll find out Tuesday morning" [X Link](https://x.com/DeepSouthDoctor/status/2012389674359152831) 2026-01-17T05:01Z [----] followers, [----] engagements "@anthonystaj @avidresearch If either of you haven't yet watched Brad Loncar's "Biotech TV" interview with Brian Skorney about $XENE here is the link below. https://www.biotechtv.com/post/brian-skorney-january-12-2025 https://www.biotechtv.com/post/brian-skorney-january-12-2025" [X Link](https://x.com/DeepSouthDoctor/status/2012559076270481758) 2026-01-17T16:14Z [----] followers, [---] engagements "$SLNO - sold for penny profits. Just like others better wanted to raise cash and the market seems pretty blas about the stock these days" [X Link](https://x.com/anyuser/status/2013650726984024482) 2026-01-20T16:31Z [----] followers, [----] engagements "Shorted my 1st biotech of [----]. Never hold shorts for very long just one way of hedging against a frothy market. Hint - I shorted them last month at a considerably higher price took decent profits quickly but way premature. Although to be fair I put profits to good use" [X Link](https://x.com/anyuser/status/2014405819748483417) 2026-01-22T18:32Z [----] followers, [----] engagements "@AAMortazavi All you have to do is look at my last [--] weeks of tweets. $KYMR" [X Link](https://x.com/DeepSouthDoctor/status/2014407434706592071) 2026-01-22T18:38Z [----] followers, [---] engagements "$VIR - up 25% this week on no news. You never know when (perceived) undervalued stocks begin to move up. Of course a much anticipated catalyst is coming up late next month but stock's recent strength is noteworthy. I remain long and holding" [X Link](https://x.com/anyuser/status/2014735355249877258) 2026-01-23T16:21Z [----] followers, [----] engagements "@ZwerBio I appreciate the perspective especially. b/c I don't follow $JANX. However I don't think their partnering news explains $VIR strength all week or the magnitude of their increase" [X Link](https://x.com/DeepSouthDoctor/status/2014745070390374623) 2026-01-23T17:00Z [----] followers, [---] engagements "$CRVS - bought back a chunk on the "mini-dip". While happy to buy back these shares at lower that what I last sold - remember I also sold some in the teens - I mainly want to direct more funds to bios that I feel are super solid - both with data trial design & management" [X Link](https://x.com/anyuser/status/2017283275421548908) 2026-01-30T17:06Z [----] followers, [----] engagements "$AVBP - bought full position $21 past two trading days. May be a bit early but am bullish on Ph3 readout (Q126) in Exon20 nsclc and like other trials as well. 9% Insider ownership nice to see" [X Link](https://x.com/DeepSouthDoctor/status/1949818372247687605) 2025-07-28T13:05Z [----] followers, [----] engagements "$EOLS - sold yesterday for a sizable loss. I will con't to follow them as I think they might turn things around by Q4 - supposedly 1st profitable quarter - or Q126 but they've clearly lost the confidence of investors given significant under-performance past [--] quarters" [X Link](https://x.com/DeepSouthDoctor/status/1953439733876494458) 2025-08-07T12:55Z [----] followers, [----] engagements "Most of the Commercialization-stage bios that I follow (and generally like) are down YTD and down significantly from their 52-week highs despite biotech indices being up YTD and after a strong Q425. $ABEO $BCRX $CRMD $EOLS $ETON $HRMY $HROW $IOVA $OCUL $RIGL $SLNO $TARS $URGN" [X Link](https://x.com/anyuser/status/2015204062531088860) 2026-01-24T23:24Z [----] followers, [----] engagements "Holding several bios w major Q1 data catalysts: $IDYA $IOVA $MYLS $OCUL $VIR Holding $SPRB w Q1 catalyst of filing sNDA YTD I'm 1-1 on major catalysts. Thankfully $CRVS gain $GUTS loss. Still holding $TCMD $TECX $CRVS Will re-evaluate $CRMD after Feb10 Analyst Day" [X Link](https://x.com/anyuser/status/2019862210751668304) 2026-02-06T19:54Z [----] followers, [----] engagements "@BlaseBio They're way too small of a company to commercialize on their own a drug that would be primarily prescribed by Primary Care docs. It's one thing to sell a rare disease drug or one marketed to specialists but $MLYS is right to look for a partner" [X Link](https://x.com/DeepSouthDoctor/status/2020370241650585965) 2026-02-08T05:32Z [----] followers, [---] engagements "Red days are for buying. Bought full position last few days in $PVLA Re-bought full position in $XENE this morning. Both with Ph3 readouts next month very bullish on both" [X Link](https://x.com/anyuser/status/2021600435757265383) 2026-02-11T15:01Z [----] followers, [----] engagements "@binarypharmer I prefer $MGDL over $VKTX. No substitute for their much larger Ph2b done in actual NASH population" [X Link](https://x.com/DeepSouthDoctor/status/1070708674853855232) 2018-12-06T15:56Z [----] followers, [--] engagements "I've been following $CCXI for a long time (and am a definite bull). IMO the Q3 earnings call transcript lays out the case for Avacapan better than any previous talks/presentations. Encourage bioinvestors to read the transcript via SA" [X Link](https://x.com/DeepSouthDoctor/status/1191724158863982593) 2019-11-05T14:29Z [----] followers, [--] engagements "@lblegend33 @Miljenkoz @65 People are waiting for them to make a statement about to what extent the Ph3 trial might be delayed. Too the short-term attention span of (biotech) investors means $MGDL will still likely be a bargain more than a year from now. Meantime remember the raises at $305 and $108" [X Link](https://x.com/DeepSouthDoctor/status/1245405063486545920) 2020-04-01T17:38Z [----] followers, [--] engagements "$ONCT was at $1.7 at the end of Q320. Since that time they really haven't released significant new data. Now it has gone up more than 5x. Biotech can be a funny game. Bought $ONCT past two days. For a micro-cap bio they have [--] different Ph1/2 data set readouts this quarter. Already have excellent preliminary data in MCL good data in CLL and just nabbed a RPDD for 3rd indication in r/r Ewing's Sarcoma. All that & an EV $25m Bought $ONCT past two days. For a micro-cap bio they have [--] different Ph1/2 data set readouts this quarter. Already have excellent preliminary data in MCL good data in CLL" [X Link](https://x.com/DeepSouthDoctor/status/1372193663468634115) 2021-03-17T14:30Z [----] followers, [--] engagements "It is beyond me to understand why $CLRB has an EV of $15m with their pipeline data and balance sheet" [X Link](https://x.com/DeepSouthDoctor/status/1393611296776638466) 2021-05-15T16:56Z [----] followers, [--] engagements "Bought some $EIGR. Don't know if it (and $MGDL $EYEN) are suffering by association with $MIST but $EIGR's lead drug is for HepD where there are no approved txs. Ph3 data coming this Q - it's not a slam dunk but am pretty bullish and has BTD/PRIME status" [X Link](https://x.com/DeepSouthDoctor/status/1582790057471401984) 2022-10-19T17:45Z [----] followers, [--] engagements "$RAIN strong of late on unusually robust volume. Given that 52-week high is $16 and my bullish view of Ph3 trial prospects content to hold thru Q123 data. Re-established position (thankfully able to buy more shares) in $RAIN $6 ahead of pivotal Q123 readout. Would like to add even a few more shares if it re-traces a bit. Still seems to be flying under the radar with very low volume (except for today). Re-established position (thankfully able to buy more shares) in $RAIN $6 ahead of pivotal Q123 readout. Would like to add even a few more shares if it re-traces a bit. Still seems to be flying" [X Link](https://x.com/DeepSouthDoctor/status/1595095208433418240) 2022-11-22T16:41Z [----] followers, [--] engagements "Current holdings in order of weighting: $BTAI $ZYME* $PRVB $RAIN# $TSHA# $PHAT# $XFOR* $EIGR* $AUTL* * = Q4 data readouts # = Q123 data readouts $BTAI & $PRVB I just still like on a valuation basis even after significant appreciation from cost basis" [X Link](https://x.com/DeepSouthDoctor/status/1597632907371171842) 2022-11-29T16:45Z [----] followers, [--] engagements "$MGDL is the latest example of a stock really taking off based on trial data because the Ph3 and/or binary to the company results clearly exceeded "Street" expectations. See $AUPH $CCXI in years past (and on a % basis they appreciated more). Congrats to $MDGL longs" [X Link](https://x.com/DeepSouthDoctor/status/1605565415614164992) 2022-12-21T14:06Z [----] followers, [----] engagements "$RAIN - sold 50% of my shares at 95% profit. Remain bullish on (binary) Ph3 readout but seemed prudent to take some money off the table. Looking forward to data readout this Q" [X Link](https://x.com/DeepSouthDoctor/status/1612832321337442304) 2023-01-10T15:22Z [----] followers, [----] engagements "Current positions in order of $$: $BTAI $ZYME $LIAN $MIRM $PHAT $GTHX $ACHV $PRAX 1st [--] choices are longer-term holds latter [--] geared to near-term data catalysts or w ith $PHAT clarity w FDA). Want to buy back $PRVB $RAIN at right price $TCON when I can avoid "wash loss"" [X Link](https://x.com/DeepSouthDoctor/status/1613212177502011392) 2023-01-11T16:32Z [----] followers, [----] engagements "$PRAX now up 55% on [---] million share volume (avg. daily volume = 464K). Wonder who is driving the volume" [X Link](https://x.com/DeepSouthDoctor/status/1613919518471888897) 2023-01-13T15:22Z [----] followers, [----] engagements "Re-bought $RAIN at $9.80 after selling last week at $12.84. Fundamentals remain the same am bullish on the Ph3 trial that reads out this Q. Happy to take advantage of stock price volatility" [X Link](https://x.com/DeepSouthDoctor/status/1615364602350678018) 2023-01-17T15:05Z [----] followers, [----] engagements "$RAIN with big move today on huge volume. I guess somebody else is bullish about imminent Ph3 data" [X Link](https://x.com/DeepSouthDoctor/status/1624080893319970817) 2023-02-10T16:20Z [----] followers, [----] engagements "Unusual play for me but bought $SGEN. Buyout price (all cash offer) is 16% above current price deal to close around YE23. A lot better than any money market happy to park some funds there. (And there is always a slight chance another suitor comes along w better offer.)" [X Link](https://x.com/DeepSouthDoctor/status/1635638392447705088) 2023-03-14T13:45Z [----] followers, [----] engagements "Top [--] biotechs trading at greater than a negative $100m EV: $LIAN (long) $CMRX $KRON (no position in latter 2). In my view legit companies with real pipelines and story. I welcome additions to the list" [X Link](https://x.com/DeepSouthDoctor/status/1636725872609591300) 2023-03-17T13:47Z [----] followers, [----] engagements "Interesting stock price action in $ALT and $SELB. Don't follow either closely but stocks are way down on heels of seemingly decent data readouts. Obviously they don't put all relevant info into the PR - or were expectations just out of whack" [X Link](https://x.com/DeepSouthDoctor/status/1638180943235018752) 2023-03-21T14:09Z [----] followers, [----] engagements "Q123 Portfolio update: Biggest winners: $PRVB $ACHV $RAIN $ZYME Biggest losers: $GTHX $TSHA $PRAX Current holdings in order of size: $ACHV $BTAI $AXSM $LIAN $RAIN $XERS $MRSN $PDSB $XFOR $PHAT $SRTS Portfolio Update: (I only buy/sell long positions in micro-cap SMID-cap biotechs no shorting no options). Q123 performance: up 58% vs. S&P500 (+7%) NBI (-2%) XBI (-7%) YE16 to YE22 Last [--] full yrs Annual Average Performance: Up 31% vs. XBI (+ 6%) NBI (+ 7%) Portfolio Update: (I only buy/sell long positions in micro-cap SMID-cap biotechs no shorting no options). Q123 performance: up 58% vs. S&P500" [X Link](https://x.com/DeepSouthDoctor/status/1642878966145990657) 2023-04-03T13:17Z [----] followers, [----] engagements "Q223/Q323 Ph3 data catalysts I am watching closely: $ACHV* $APLT $AXSM* $BTAI* $CBAY $CRNX $LIAN* $MIRM $MRSN* $RAIN* $TVTX $XFOR* * = I am long Am bullish on all the ones I own plus $CRNX lukewarm on $MIRM prefer to be on sidelines for others" [X Link](https://x.com/DeepSouthDoctor/status/1642880517442772998) 2023-04-03T13:23Z [----] followers, [----] engagements "Current positions in order of size: $SGEN $BTAI** $ACHV** $AXSM** $XERS $XFOR** $MRSN** $ASLN** $RAIN** $SRTS $ARAV** ** = key Ph2b or Ph3 data either Q223 or mid23 ($MRSN $ARAV). Am treating $SGEN like a high-yield money market acct. Eyeing $CHRS post Q1 earnings call" [X Link](https://x.com/DeepSouthDoctor/status/1653412998822731777) 2023-05-02T14:55Z [----] followers, [----] engagements "Re-sold $RAIN for minor profits (after huge gains in Q1). At $10+ R/R is a tossup and want to take a final more detached re-assessment of Ph3 data prospects this Q. Too having a huge year (+ 120% YTD) & likely volatility w debt crisis make me want to build up cash reserves" [X Link](https://x.com/DeepSouthDoctor/status/1658867985598095362) 2023-05-17T16:12Z [----] followers, [----] engagements "@JamesEKrause See Brad Loncar's @bradloncar TV" interview with $SGEN CEO. Brad saves it for the last question of the interview" [X Link](https://x.com/DeepSouthDoctor/status/1665736725610496002) 2023-06-05T15:05Z [----] followers, [--] engagements "@BoitechB @JamesEKrause @bradloncar The $SGEN CEO said he absolutely expects a 2nd request" [X Link](https://x.com/DeepSouthDoctor/status/1665801646109065219) 2023-06-05T19:23Z [----] followers, [--] engagements "$DAWN -- (Part 1) It's fair to debate what is a reasonable valuation here - and how one arrives at it. I have little doubt that Tovo is approved mid-24 but signf sales not till 1H25 w reimbursement timelines. Ph3 1L LGG data not till 2H25 so 2nd appr indic not till YE26" [X Link](https://x.com/DeepSouthDoctor/status/1667944291862183937) 2023-06-11T17:18Z [----] followers, [----] engagements "$DAWN (Part 2) Stock price has gone from My'21 IPO @ $16 to Jn'22 raise at $16 to Jn'23 raise @ $13. Current MC=$1.06B w post-raise cash of $460m. They can sell RPDD voucher but will burn $40m+ each Q for next few years. I never assume a b/o. So PT & evaluation method $DAWN -- (Part 1) It's fair to debate what is a reasonable valuation here - and how one arrives at it. I have little doubt that Tovo is approved mid-24 but signf sales not till 1H25 w reimbursement timelines. Ph3 1L LGG data not till 2H25 so 2nd appr indic not till YE26 $DAWN -- (Part 1) It's fair to debate what is a reasonable" [X Link](https://x.com/DeepSouthDoctor/status/1667946012953001986) 2023-06-11T17:24Z [----] followers, [----] engagements "$MRSN: Had sold for profits b/c I thought valuation was too high skewing risk/reward. Am very surprised though by today's news. Taking profits and/or avoiding big losses (see prior tweets on $RAIN) is as important to portfolio management as identifying big winners. Bought $MRSN past few trading days. Am bullish on Ph3 UpRi trial in PROC reporting mid-23 (and they want a Euro partner) w add'l trials ongoing GSK option (after already paying $100m upfront) for [----] & research deals w JAN MRK that yielded $70m cash $1.8B+ milestones. Bought $MRSN past few trading days. Am bullish on Ph3 UpRi" [X Link](https://x.com/DeepSouthDoctor/status/1669362040647958528) 2023-06-15T15:11Z [----] followers, [----] engagements "Current positions in order of size: $SGEN $BTAI $XERS $PDSB $XFOR $ACHV $CHRS $KALV $GRTX $ASLN Surprised that $ASLN seemingly flying under the radar w Ph2b data in modr-svr atopic derm coming early July. $BTAI $XFOR have near-term data readouts $GRTX PDUFA date as well" [X Link](https://x.com/DeepSouthDoctor/status/1669395893085143063) 2023-06-15T17:26Z [----] followers, [--] engagements "Added to $CHRS today. Long-term hold. Will be interesting to see $SURF's updated data this month for their lead candidate. Like CHRS's efforts to diversify projected near-future revenues" [X Link](https://x.com/DeepSouthDoctor/status/1669701833298792449) 2023-06-16T13:41Z [----] followers, [--] engagements "@mathcoredad I give 'em credit for bolstering their biosim portfolio (Eylea) and d/c'ing one they felt wasn't going to pan out. Kudos too for diversifying beyond biosims. While any cancer drug in dev'l is a likely eventual fail $SURF's pipeline comes cheap. And I love Topi's data to date" [X Link](https://x.com/DeepSouthDoctor/status/1669938452090191872) 2023-06-17T05:22Z [----] followers, [--] engagements "@arkabagchi24 I sold $RAIN before Ph3 results came out (and made a lot of money on them earlier). I've also sold $ARAV. Tweeted about both decisions at the time" [X Link](https://x.com/DeepSouthDoctor/status/1672464671083724800) 2023-06-24T04:46Z [----] followers, [--] engagements "Re-bought $MIRM for a few cents more from where I sold in April. Like the synergistic purchase of $TVTX products and like their chances for significant results for their [--] Q4 Ph2/3 trials. I never anticipate a b/o but always liked them much more than $ALBO" [X Link](https://x.com/DeepSouthDoctor/status/1687126074453360640) 2023-08-03T15:39Z [----] followers, [----] engagements "$LYRA: Also on sidelines pre-Ph2 [---] data. From what I can extrapolate very dicey to predict magnitude of effect (vs. plcb) N = only [--] per cell & not using best PE measure. Conversely I am bullish on Ph3 [---] w data Q224 and I do see stock as pretty cheap at these levels" [X Link](https://x.com/DeepSouthDoctor/status/1699048734779191632) 2023-09-05T13:15Z [----] followers, [----] engagements "$MIRM with [--] Ph2/3 readouts due Q423 + a Dec. PDUFA date for 2nd indication for Livmarli is up strong on a day when the biotech & small-cap markets are down. Acquisition of $TVTX products provide add'l downside protection while upside is quite significant if trials succeed" [X Link](https://x.com/DeepSouthDoctor/status/1699114788050063490) 2023-09-05T17:38Z [----] followers, [----] engagements "$SNDX has been making new 52-week lows daily for the past week or so in advance of (supposedly) Q3 Ph3 data readout in acute leukemia. Will be interesting to see how this plays out. (I have no position b/c I am not enthusiastically bullish about Ph3 prospects.)" [X Link](https://x.com/DeepSouthDoctor/status/1707758964677423562) 2023-09-29T14:07Z [----] followers, [----] engagements "@jfais20 In general yes. However $CHRS management has been clear that Yusimry uptake will be much slower with different issues related to gaining market share. ($CHRS is my #1 holding.)" [X Link](https://x.com/DeepSouthDoctor/status/1709611708170318254) 2023-10-04T16:49Z [----] followers, [---] engagements "@OldgrapeRX You are leaving out Eylea biosim launch in Q225 will be a significant contributor to revenue ultimately likely their biggest revenue producer" [X Link](https://x.com/DeepSouthDoctor/status/1721919473613988112) 2023-11-07T15:56Z [----] followers, [---] engagements "Bought $MOR. I don't get hyper-focus on 2nd endpt. of TSS50. Very confident Ph3 (data end of Nov. then oral talk at ASH) hits the sole PE think it hits on most secondaries and "totality of data" will clearly be SOC AND approvable. Buying when others run to the exits" [X Link](https://x.com/DeepSouthDoctor/status/1725533265153454171) 2023-11-17T15:16Z [----] followers, [----] engagements "Sold $MOR into strength for small profit. Sell-off after initial data release was excessive nice to see stock recover going into ASH presentation. Bought $MOR. I don't get hyper-focus on 2nd endpt. of TSS50. Very confident Ph3 (data end of Nov. then oral talk at ASH) hits the sole PE think it hits on most secondaries and "totality of data" will clearly be SOC AND approvable. Buying when others run to the exits. Bought $MOR. I don't get hyper-focus on 2nd endpt. of TSS50. Very confident Ph3 (data end of Nov. then oral talk at ASH) hits the sole PE think it hits on most secondaries and" [X Link](https://x.com/DeepSouthDoctor/status/1730240314055471208) 2023-11-30T15:00Z [----] followers, [----] engagements "Bought back into $SGEN at $213.00. Seems like a good place to park cash. Expecting PFE takeover at $229 to go through by YE23 or early Q124" [X Link](https://x.com/DeepSouthDoctor/status/1730261620318666946) 2023-11-30T16:24Z [----] followers, [----] engagements "Bought $CLRB last week. Am bullish on their Ph3 readout coming up at JPM in [--] weeks. Conversely am aghast at history of [--] reverse splits over past [--] yrs. I do think their lead drug is active though w low bar for success in indication w/o an approved tx" [X Link](https://x.com/anyuser/status/1734216428603965725) 2023-12-11T14:19Z [--] followers, [----] engagements "$KALV - went from early morning red to big green move on strong volume. Con't to hold thru early Q1 Ph3 data for on-demand HAE tx. Very bullish on trial" [X Link](https://x.com/DeepSouthDoctor/status/1734314072777069054) 2023-12-11T20:47Z [----] followers, [---] engagements "That worked out well. Doesn't make up though for selling $MOR (into strength) too early. Not many boring days in biotech. Bought back into $SGEN at $213.00. Seems like a good place to park cash. Expecting PFE takeover at $229 to go through by YE23 or early Q124. Bought back into $SGEN at $213.00. Seems like a good place to park cash. Expecting PFE takeover at $229 to go through by YE23 or early Q124" [X Link](https://x.com/anyuser/status/1734643698070179900) 2023-12-12T18:37Z [--] followers, [----] engagements "$ACHV: Listened to CEO's interview at Life Science Forum. Of course he said they were blindsided by FDA request for l-t safety data. Topic of company balance sheet was blithely ignored. They want/expect to have a w/w part on board by Q224. If so they'll be fine. If not . . " [X Link](https://x.com/DeepSouthDoctor/status/1735666022936453174) 2023-12-15T14:20Z [----] followers, [----] engagements "$ACRS: Mixed feelings about corporate update. However company (at $0.80) has a $59m market cap with a $202m cash balance and a reduced burn rate going forward. So surprised downside move is so strong expect it to bounce a bit from this level" [X Link](https://x.com/DeepSouthDoctor/status/1737482595682705672) 2023-12-20T14:38Z [----] followers, [----] engagements "2023 Stats Part 2: I owned [--] different bios in [----] profited in [--] (61%). Biggest Winners: $PRVB $RAIN $MIRM Biggest Losers: $GRTX $GTHX Sold too Soon: $CBAY $CRNX $LIAN" [X Link](https://x.com/DeepSouthDoctor/status/1742184825195307083) 2024-01-02T14:03Z [----] followers, [----] engagements "$CHRS: Listened to the call this a.m. I applaud the transaction - they leveraged their strengths (e.g. higher margin products Loqtorzi & Casdozo data) and shored up their weaknesses (e.g. balance sheet). Potential future deals await (e.g. selling Yusimri ex-USA partners)" [X Link](https://x.com/DeepSouthDoctor/status/1749470201668575349) 2024-01-22T16:32Z [----] followers, [----] engagements "$CHRS: At current price stock selling for well 2x [----] proj. revenues w much improved balance sheet. Is the primary perception negative that they've mostly failed w their biosimilars or positive that they've nimbly pivoted/narrowed their focus aided by shrewd deal-making" [X Link](https://x.com/DeepSouthDoctor/status/1749504471644701163) 2024-01-22T18:49Z [----] followers, [----] engagements "@sunrgu Yeah lots of moving parts here. I don't think investors will get a really clear view until maybe the Q124 or even Q224 earnings call - [--] months after Loqtorzi launch deal closure headcount reduction planned add'l oncology trials potential add'l partnering or co-dev'l deals" [X Link](https://x.com/DeepSouthDoctor/status/1749521306356261053) 2024-01-22T19:55Z [----] followers, [---] engagements "@IvanmacMac Even if they beat estimates still seems overvalued to me. And next pipeline products are only in Ph2a" [X Link](https://x.com/DeepSouthDoctor/status/1752004940774420780) 2024-01-29T16:25Z [----] followers, [--] engagements "@ZbJohnson124 Of the ones I follow closely - $LYRA $NARI $PHAT" [X Link](https://x.com/DeepSouthDoctor/status/1757081155550003274) 2024-02-12T16:36Z [----] followers, [---] engagements "@drobne9 I probably won't hold them long-term but I don't expect to settle for a loss either so let's see how the Q4 earnings call goes" [X Link](https://x.com/DeepSouthDoctor/status/1757555286556950941) 2024-02-14T00:00Z [----] followers, [--] engagements "$SWTX: I dont' understand the valuation. Launched 1st drug YE23 now w an EV over $3B. Who'd pay a premium to that to buy them out Projected [----] sales are $65m. How does one account for current valuation Sign to me that in places biotech market is getting quite frothy" [X Link](https://x.com/DeepSouthDoctor/status/1758568096220995639) 2024-02-16T19:04Z [----] followers, [----] engagements "@meraghumittal M & A almost not mentioned at all. While I trust management's acumen to make a sound acquisition I don't see it occurring until Q4 at earliest b/c I think Ph2 data/Ph3 requirements and commercial performance of products are needed to clarify how to allocate $ going forward" [X Link](https://x.com/DeepSouthDoctor/status/1765451723491987866) 2024-03-06T18:57Z [----] followers, [---] engagements "$CHRS: Listened to earnings call. Best tidbit: Loqtorzi is predicted to reach peak sales of $200m in its initial indication in [--] 1/2-3 years. Along with Udencya's increased market share con't to ramp up seems clear that they will achieve sustained profitability from 1H25" [X Link](https://x.com/DeepSouthDoctor/status/1768089938141048993) 2024-03-14T01:41Z [----] followers, [----] engagements "@bio_report We won't really get a true picture until the Q2 earnings call - and analysts like to be spoon-fed guidance. However company has made several moves to reduce expenses" [X Link](https://x.com/DeepSouthDoctor/status/1768111967699407284) 2024-03-14T03:08Z [----] followers, [--] engagements "$NARI making new 52-week lows not getting any love from the market. A bit puzzled as to why but no mistaking the trend" [X Link](https://x.com/DeepSouthDoctor/status/1768669928184303959) 2024-03-15T16:05Z [----] followers, [----] engagements "$SGMT: I'm a buyer here. Stock was at $6.50 before release of Ph2b NASH data. Stock zooms to $18+ post Jan 22nd data release. Retraces a bit next [--] days as they do a raise at $12.50. Now stock at $4.10 on no subsequent news. MC=$132m Cash=$208m no debt. Go figure" [X Link](https://x.com/DeepSouthDoctor/status/1769721453581078968) 2024-03-18T13:44Z [----] followers, [----] engagements "Based on formula below of the bios I follow I come up with: Great Value: $CHRS $ESPR $AUPH $ETON (i.e. EV/prod rev = [---] profitability in [----] and/or [----]. Good/Fair Value: $ACAD $HROW $XERS $CPRX $RVNC $NARI Poor Value: $PHAT $TGTX $TARS $ARQT Valuation food for thought: I rate micro/smid-cap bios using the formula: EV divided by FY24 product revenue. Same for FY25 product revenue. EV = market cap + debt minus cash plus/minus FY burn rate/profitability rate. This formula doesn't assess pipeline or growth rate. Valuation food for thought: I rate micro/smid-cap bios using the formula: EV" [X Link](https://x.com/DeepSouthDoctor/status/1772247040623251863) 2024-03-25T12:59Z [----] followers, [----] engagements "@OldgrapeRX @Dreesenkl Think of the formula I proposed as a useful screen then one can add in patent issues projected growth rate pipeline and balance sheet considerations. Those are a lot of extra variables but I still think the formula is an effective screen and focused on current valuation" [X Link](https://x.com/DeepSouthDoctor/status/1772318376502686087) 2024-03-25T17:43Z [----] followers, [---] engagements "@stock_khoj @semodough They cash in $35m in warrants post-approval want to sign partnership deals ex-USA and should have no trouble either raising cash via a secondary or using non-dilutive funding that is paid back via royalties. Bottom line I'm not worried about their balance sheet" [X Link](https://x.com/DeepSouthDoctor/status/1774125019997549039) 2024-03-30T17:22Z [----] followers, [---] engagements "Bought $ETON past few trading days. [--] consectv Qs of sequential growth - which should con't for next few years at least - and profitable in [----]. Superb EV/revenue ratio clean balance sheet. Niche player in ultra-rare orphan disease w [--] prod on market aiming for [--] by YE25" [X Link](https://x.com/DeepSouthDoctor/status/1775149170724094191) 2024-04-02T13:11Z [----] followers, [---] engagements "@jfais20 @Maximus_Holla Interneuron Pharmaceuticals holding tons into Ph3 binary stroke trial. Was over [--] years ago and still stands out as the worst mistake b/c I had an embarrassingly large % of my entire funds wrapped up in it" [X Link](https://x.com/DeepSouthDoctor/status/1776328834427601309) 2024-04-05T19:19Z [----] followers, [---] engagements "Bought $LYRA. Very bullish on Ph3 trial in pre-surg chronic sinusitis due to report this Q. Ph2 results were signf dose-dep and improved over time. Now Ph3 with best PE N=120 vs. [--] (tx. group/plcb) vs Ph2 of [--] per cell. Has China part balance sheet not an immediate issue" [X Link](https://x.com/DeepSouthDoctor/status/1777336463413125256) 2024-04-08T14:03Z [----] followers, [----] engagements "@AConfidenceGame Yeah but when they be coming to market with their product in best case scenario" [X Link](https://x.com/DeepSouthDoctor/status/1778823977302904903) 2024-04-12T16:34Z [----] followers, [---] engagements "$HROW - sold entire position for moderate profits. Wanted to raise cash company not as undervalued as others I like and unclear if they hit April guideline of delivering a successful manufacturing batch of Triesic" [X Link](https://x.com/DeepSouthDoctor/status/1780624915525230802) 2024-04-17T15:50Z [----] followers, [----] engagements "Current positions in order of size: $CLRB $MIRM $ESPR $ETON $SGMT $CHRS $ANNX (recently sold 20% of $CHRS for minimal loss)" [X Link](https://x.com/DeepSouthDoctor/status/1780643586603680053) 2024-04-17T17:04Z [----] followers, [----] engagements "@arreglalo Sold recently to take long-term capital gains. Hope to buy back in Q4 or so as my long-term view of company hasn't changed. I do think it's now unlikely though that a partner won't sign on until at least NDA acceptance of filing" [X Link](https://x.com/DeepSouthDoctor/status/1780661025181733342) 2024-04-17T18:14Z [----] followers, [---] engagements "$ETON - bought 10% more on Friday an undiscovered/ underfollowed gem IMHO. [--] consecutive quarters of sequential growth will con't for the foreseeable future. Management savvy and disciplined balance sheet not a problem at virtual break-even now solidly profitable in 2025" [X Link](https://x.com/DeepSouthDoctor/status/1789986598752231759) 2024-05-13T11:50Z [----] followers, [----] engagements "$AVTE - bought a 1/2 position on Friday at $19.95 following dip. Ph2b data w novel formulation for PAH due in June. Same/better efficacy much better safety than comp. Obviously bullish on trial - company seamlessly began the Ph3 in Q423 so would think Ph2b results are solid" [X Link](https://x.com/DeepSouthDoctor/status/1789987718417490212) 2024-05-13T11:55Z [----] followers, [----] engagements "$CHRS - sold the last of it my biggest loss in past [--] yrs. Was waiting for last chunk to become a long-term cap loss. No excuses here. They need to continue to clean up the balance sheet and get leaner and more focused as a company should have more clarity in [--] mos" [X Link](https://x.com/DeepSouthDoctor/status/1794001668100522469) 2024-05-24T13:45Z [----] followers, [----] engagements "@JTT20222021 I use a crude metric of: (Market cap + Long-term debt) - cash divided by [----] product revenue (and repeat same for [----] product revenue estimates). I also adjust for projected profitability or burn rate. By that metric I don't see them as cheap" [X Link](https://x.com/DeepSouthDoctor/status/1798083042986303930) 2024-06-04T20:02Z [----] followers, [--] engagements "$ESPR - Love the deal to bring in $300+ million in cash to transform the balance sheet while having royalties revert back after payment cap reached. They "under-promised and over-delovwted"" [X Link](https://x.com/DeepSouthDoctor/status/1806669924342878631) 2024-06-28T12:44Z [----] followers, [----] engagements "$ETON - listened to Q2 earnings call remain very bullish. [--] consecutive quarters of revenue growth cash flow positive bigger acquisitions to come this year. Relatively unknown my fave long-term hold" [X Link](https://x.com/DeepSouthDoctor/status/1821890498757357870) 2024-08-09T12:45Z [----] followers, [---] engagements "@Dancingtapas For me the Q3 earnings release will be key. Management has been stating that this is when sales will begin to ramp significantly and I think we'll get the clearest look yet at the balance sheet. Minimal downside from here so I'm still holding all shares" [X Link](https://x.com/DeepSouthDoctor/status/1826059622085701995) 2024-08-21T00:51Z [----] followers, [--] engagements "@jfais20 $IOBT is an immediate multi-bagger if its trial hits its PE at the interim look (likely this Q). $ETON is my fave long-term hold management hinted during CC at big acquisitions coming before YE. $CLRB - want to see Q4 data update as if good partnership/buyout chances go up" [X Link](https://x.com/DeepSouthDoctor/status/1826601870909165751) 2024-08-22T12:46Z [----] followers, [----] engagements "@semodough Yeah I'm also questioning that the data came only from China. $SMMT has a long way to go to get to market" [X Link](https://x.com/DeepSouthDoctor/status/1833931635093635323) 2024-09-11T18:12Z [----] followers, [---] engagements "$SMMT - waiting to see at what level the positive momentum stops. Now at $22 Billion market cap. Wow Is it just me or is it a little premature for $SMMT to have a market cap of $17 Billion w/o having a drug on market until at least [----] Is it just me or is it a little premature for $SMMT to have a market cap of $17 Billion w/o having a drug on market until at least 2006" [X Link](https://x.com/DeepSouthDoctor/status/1834589336483897727) 2024-09-13T13:45Z [----] followers, [----] engagements "$TIL -They're crazy if they don't raise money in the next few days. Nice market cap for a product in Ph1" [X Link](https://x.com/DeepSouthDoctor/status/1834660842802978988) 2024-09-13T18:30Z [----] followers, [----] engagements "@ShoshinValue @HRow $ETON will easily exceed $50m but pace of growth is yoked to new products coming to market thru pipeline or acquisition. Many quarters/years of growth to come and they've hinted at bringing on drugs w higher peak sales potential. I'm just going to enjoy the long-term ride" [X Link](https://x.com/DeepSouthDoctor/status/1834783724229021848) 2024-09-14T02:38Z [----] followers, [---] engagements "@PaulAtreidesBio Bravery or stupidity - hard to tell. Problem is I KNOW the MC is irrational but markets (in a stock or sector) can continue to be irrational. Hopefully investors will sober up over the weekend and we'll see a pullback (soon)" [X Link](https://x.com/DeepSouthDoctor/status/1834784236865216787) 2024-09-14T02:40Z [----] followers, [---] engagements "@wshao8 "business development" - i.e. acquisitions partnering etc. For $ETON it means acquiring additional commercial-stage products. They hinted on Q2 earnings call that a deal or two were in the works and they've previously said their goal is to have [--] products by YE25" [X Link](https://x.com/DeepSouthDoctor/status/1836495425928413350) 2024-09-18T20:00Z [----] followers, [--] engagements "@ShoshinValue I don't see a downside scenario that is realistic or that could readily be anticipated. Perhaps if they ran into regulatory issues that delayed approvals of new drugs or they way over-spend for an acquisition. Neither has happened before though" [X Link](https://x.com/DeepSouthDoctor/status/1836830165424558346) 2024-09-19T18:10Z [----] followers, [---] engagements "Re-bought $SCPH. I think they're now building momentum and hoping for a long steady grind upwards. A long-term hold should see sequential growth for many quarters to come. Quite cheap vs. other micro/small-cap commercialization stage bios" [X Link](https://x.com/DeepSouthDoctor/status/1838235208245543164) 2024-09-23T15:13Z [----] followers, [---] engagements "Biotech thoughts for the day: $ETON con't to make new 52-week highs on strong volume. $ARWR and $URGN con't to droop to near 52-week lows - deservedly IMHO. $ACAD near 52-week lows but interests me at this valuation" [X Link](https://x.com/DeepSouthDoctor/status/1844020975224131702) 2024-10-09T14:23Z [----] followers, [----] engagements "Current holdings in order of size: $ETON $ESPR $SCPH $CELC $ACHV $CADL $ACRV. Stalking: $NAMS $SGMT $VNDA" [X Link](https://x.com/DeepSouthDoctor/status/1844732725132955730) 2024-10-11T13:32Z [----] followers, [----] engagements "$NARI is just 10% off of 5+ multi-year lows. Excellent example of: 1) The difficulty of transitioning to a commercial-stage biotech (shared by so many others). 2) A reminder that innovation does not necessarily lead to proper valuation. Red Sox sent $250K of international money to Yankees in that trade per source. Red Sox sent $250K of international money to Yankees in that trade per source" [X Link](https://x.com/DeepSouthDoctor/status/1844738465591644626) 2024-10-11T13:54Z [----] followers, [----] engagements "@SaicharanAitha I've traded it in the past as well - valuation seems absurd and management is motivated to partner" [X Link](https://x.com/DeepSouthDoctor/status/1846567822450635151) 2024-10-16T15:04Z [----] followers, [--] engagements "$ESPR is up 33% since beginning of month. Bodes well for management delivering on guidance that Q3 would begin the significant ramping up of sales. Like the positive momentum going into Q3 earnings call next month. Still wildly undervalued IMHO" [X Link](https://x.com/DeepSouthDoctor/status/1846568676729688122) 2024-10-16T15:07Z [----] followers, [----] engagements "@monaco_biotech I agree with you. I think it is at least 50/50 that they get a deal done by end of Q125" [X Link](https://x.com/DeepSouthDoctor/status/1846709731278102636) 2024-10-17T00:28Z [----] followers, [---] engagements "@jayabacus Bought some too hope this works out like $SGEN" [X Link](https://x.com/DeepSouthDoctor/status/1847284077017125155) 2024-10-18T14:30Z [----] followers, [---] engagements "@PersimmonTI Follow-up question is a valuation one. $BBIO has a $4.8B market cap and given their $1.7B long-term debt it has an Enterprise Value $6B. Doesn't have enuf cash to reach break-even. Overvalued regardless of PDUFA decision" [X Link](https://x.com/DeepSouthDoctor/status/1848230758864871425) 2024-10-21T05:12Z [----] followers, [----] engagements "@semodough Doug I see $BBIO as overvalued at these levels. About a $6B Enterprise Value and not nearly enough cash to reach break-even. Yes the pipeline is enticing but the valuation is already ahead of itself" [X Link](https://x.com/DeepSouthDoctor/status/1848231619091407143) 2024-10-21T05:15Z [----] followers, [---] engagements "@Ec250940387Ec2 @semodough I don't follow $ALNY so no opinion there" [X Link](https://x.com/DeepSouthDoctor/status/1848370530778223099) 2024-10-21T14:27Z [----] followers, [----] engagements "Bio-twitter is best (for me) for reading contrary points of views of stocks I own. $ANRO joins a few other bios I've owned (e.g. $LYRA $AVTE $RAIN) and made money on but eventually sold before their data blowups. Always useful to re-visit one's positions with skepticism" [X Link](https://x.com/DeepSouthDoctor/status/1849080553607192677) 2024-10-23T13:28Z [----] followers, [----] engagements "$VKTX - bought some for a swing trade with upcoming data update. Have questions about its valuation but not about the quality of its data" [X Link](https://x.com/DeepSouthDoctor/status/1849110198989869532) 2024-10-23T15:26Z [----] followers, [----] engagements "Sold $VKTX. I'm happy with a 20% 1-day gain. Might re-buy if it re-traces significantly before data release. $VKTX - bought some for a swing trade with upcoming data update. Have questions about its valuation but not about the quality of its data. $VKTX - bought some for a swing trade with upcoming data update. Have questions about its valuation but not about the quality of its data" [X Link](https://x.com/DeepSouthDoctor/status/1849465024588263552) 2024-10-24T14:56Z [----] followers, [----] engagements "Bought $VNDA past [--] days. Problematic management Yes. Tremendously undervalued Yes. Correct to shut down low-ball buyout offers Yes. Negative EV despite having plenty of cash to get to profitability Yes" [X Link](https://x.com/DeepSouthDoctor/status/1849799239271854230) 2024-10-25T13:04Z [----] followers, [----] engagements "Re-bought $VKTX for short-term swing trade $71. In a gambling mood with Breeder's Cup weekend coming up" [X Link](https://x.com/DeepSouthDoctor/status/1852009771974414632) 2024-10-31T15:28Z [----] followers, [----] engagements "$VKTX - sold $73 to exit w some profits to now bet freely on Breeder's Cup races today and tomorrow. Per $VKTX you never know how "the street" perceives results so I am happy to just take trading profits for the 2nd time. Too I don't think they're undervalued at this stage. Re-bought $VKTX for short-term swing trade $71. In a gambling mood with Breeder's Cup weekend coming up. Re-bought $VKTX for short-term swing trade $71. In a gambling mood with Breeder's Cup weekend coming up" [X Link](https://x.com/DeepSouthDoctor/status/1852344737543430484) 2024-11-01T13:39Z [----] followers, [----] engagements "$VKTX: Kind of what I expected - excellent data muted market reaction. Now the issue is when is the next significant catalyst Next significant data release" [X Link](https://x.com/DeepSouthDoctor/status/1853451643649462531) 2024-11-04T14:58Z [----] followers, [----] engagements "$VKTX - couldn't resist re-buying at $70. Expect momentum to pick up this week" [X Link](https://x.com/DeepSouthDoctor/status/1853456172256268455) 2024-11-04T15:16Z [----] followers, [----] engagements "Bought $CRVO past [--] days at $12.34. Am bullish on Ph2b trial in DLB with data due next month. Very binary event. Given low daily volume and a MC of only $106m the potential upside is enormous. I welcome bearish POVs" [X Link](https://x.com/DeepSouthDoctor/status/1854521940939071816) 2024-11-07T13:51Z [----] followers, [----] engagements "$VNDA - sold position for about 14% 2-week profit. My opinion on company hasn't changed just having a very good year personally and I like selling into (market strength). Will be stalking stock for re-entry anytime before Q4 earnings call" [X Link](https://x.com/DeepSouthDoctor/status/1854564973092983076) 2024-11-07T16:42Z [----] followers, [---] engagements "@mathcoredad Well I'm rooting for you but you know things aren't looking good when analyst downgrades follow the earnings release CC. I held it for several months and b/c I added when it was $1.70 actually eked out a profit overall in $ESPR this year. However I am now "unfollowing" it" [X Link](https://x.com/DeepSouthDoctor/status/1854761341195628890) 2024-11-08T05:42Z [----] followers, [---] engagements "$VKTX - sold for penny profits this last time. I'm among those who think the upcoming major "catalyst desert" will work against them and I don't consider them undervalued given that they are years from market" [X Link](https://x.com/DeepSouthDoctor/status/1854898956083351728) 2024-11-08T14:49Z [----] followers, [---] engagements "Re-bought $PRTA at $17.50 past few days after selling at $23 in March. Lots of shots on goal w multiple data sets coming this Q and next. Multiple meaty corporate partnerships. Really like the R/R here" [X Link](https://x.com/DeepSouthDoctor/status/1855989353475891424) 2024-11-11T15:01Z [----] followers, [----] engagements "$VKTX: Rebought $59 for a possible short-term swing trade after selling at $70 [--] trading days ago" [X Link](https://x.com/DeepSouthDoctor/status/1856366927687389386) 2024-11-12T16:02Z [----] followers, [----] engagements "@buylowersellhih @ChrisOlin I'd look at their October slide deck then listen to the [--] minute Earnings Call today. You'll learn what you need to know. I was very encouraged by the Call will tweet about it Monday pre-market" [X Link](https://x.com/DeepSouthDoctor/status/1856529452647256348) 2024-11-13T02:48Z [----] followers, [--] engagements "$ETON - great earnings call company executing flawlessly. Interesting tidbit was management said a goal was to attain a $1B market cap - i.e. 4x current price. 💪💪" [X Link](https://x.com/DeepSouthDoctor/status/1856702442563342420) 2024-11-13T14:15Z [----] followers, [---] engagements "@ChrisOlin Let's wait for their Q3 earnings call/letter to shareholders and see what we learn" [X Link](https://x.com/DeepSouthDoctor/status/1856702813323100586) 2024-11-13T14:17Z [----] followers, [--] engagements "Sold $VKTX yesterday for day-trading profits. Have a feeling stock is going to get close to $50 if biotech market takes a breather. Never like it when stock is red on a green market day. $VKTX: Rebought $59 for a possible short-term swing trade after selling at $70 [--] trading days ago. $VKTX: Rebought $59 for a possible short-term swing trade after selling at $70 [--] trading days ago" [X Link](https://x.com/DeepSouthDoctor/status/1856710282220843136) 2024-11-13T14:46Z [----] followers, [----] engagements "Shorted $RNA again this time at $51. (Had covered a short profitably at $47 last month.) A $6.1B market cap for a company at least 2-3 years away from marketing their 1st drug seems excessive to me" [X Link](https://x.com/DeepSouthDoctor/status/1856714708469915990) 2024-11-13T15:04Z [----] followers, [----] engagements "@rddbryant @buylowersellhih @ChrisOlin Yes I thought it was an excellent call as well and was pleasantly surprised that CEO mentioned the $1B market cap goal" [X Link](https://x.com/DeepSouthDoctor/status/1856728696997998933) 2024-11-13T15:59Z [----] followers, [--] engagements "@buylowersellhih Just lets investors know that management feels they're still in early stages of their growth (which they explicitly stated). Also implies that they wouldn't entertain buyout offers that valued them at a significantly lower market cap" [X Link](https://x.com/DeepSouthDoctor/status/1856739972763554256) 2024-11-13T16:44Z [----] followers, [--] engagements "$CELC: Re-bought yesterday. After re-reviewing the data and listening to earnings call am increasingly bullish on Ph3 trial readouts in 1H25 and 2H25. Not a swing trade (barring a huge run up) will hold thru data" [X Link](https://x.com/DeepSouthDoctor/status/1857419252757622975) 2024-11-15T13:43Z [----] followers, [---] engagements "$SCPH: Sold all yesterday for moderate loss (for 2nd time). Going forward I think I need to stick with commercialization-stage bios that are either profitable or have multiple products on market" [X Link](https://x.com/DeepSouthDoctor/status/1857420890780139680) 2024-11-15T13:50Z [----] followers, [---] engagements "$BBIO - this will be interesting market cap at $5.6B w $1.7B of LTD might burn through cash ($549) in [--] year. That is almost an EV of $7B with 1st product soon to be on market. Hard to think it's undervalued but not getting in the way of its positive momentum" [X Link](https://x.com/DeepSouthDoctor/status/1861057786215370843) 2024-11-25T14:42Z [----] followers, [----] engagements "@tonyboloj I have no knowledge of the drug. However management has executed flawlessly so I'm going to assume it's a solid acquisition. Current sales force can detail it. On the way to a $1B market cap" [X Link](https://x.com/DeepSouthDoctor/status/1861174581114908942) 2024-11-25T22:26Z [----] followers, [--] engagements "$ARWR - bought at $23 after deal news today. Amazing to me that stock is still closer to 52-week lows than highs. Haven't seen a non-buyout deal of this magnitude in" [X Link](https://x.com/DeepSouthDoctor/status/1861427407288205727) 2024-11-26T15:10Z [----] followers, [----] engagements "$AXSM - why did so many patients in the narcolepsy study decline to participate in the 6-month OLE" [X Link](https://x.com/DeepSouthDoctor/status/1861453370222866535) 2024-11-26T16:54Z [----] followers, [----] engagements "Bought $CGEM yesterday full position. A long-term hold as next data sets are a few Qs in the future. Super cheap in my view pristine balance sheet. Excited to see where things stand a year from now" [X Link](https://x.com/DeepSouthDoctor/status/1864313656193745075) 2024-12-04T14:19Z [----] followers, [---] engagements "Sold $STRO and $ARWR for minor profits. I remain bullish on both just liked others better wanted to raise cash and "keep (more) powder dry" in case of downturn. Too neither has near-term major catalysts" [X Link](https://x.com/DeepSouthDoctor/status/1864351615668380037) 2024-12-04T16:50Z [----] followers, [----] engagements "$CRVO volatility has been quite intense past few weeks even for micro/small-cap biotechs. Binary Ph2b data in early DLB coming this month. At least somebody else is hopeful that good results are coming given this morning's action" [X Link](https://x.com/DeepSouthDoctor/status/1865059722082087068) 2024-12-06T15:44Z [----] followers, [----] engagements "$CMRX - Gobbled up some at the open. Expect it to really move up as news gets out. Filing for AA YE w lead drug addressing a $750m market. a $4 stock price = $360m with $152m in cash and a PRV voucher. Yes they owe milestones & royalties but stock is now dirt cheap" [X Link](https://x.com/DeepSouthDoctor/status/1866492954539372661) 2024-12-10T14:39Z [----] followers, 10.5K engagements "$CMRX - Bought 33% more soon after the open now my #2 position ($ETON is #1). Cost basis now $2.29. If company executes as planned I still believe it's significantly undervalued. Expect another boost up if they do indeed file for AA by YE" [X Link](https://x.com/DeepSouthDoctor/status/1866903216136524225) 2024-12-11T17:49Z [----] followers, [---] engagements "$CMRX - Listened to CC about filing for AA. Impressed by management have increased confidence in company's prospects. Expect stock to be a multi- bagger at this level within [--] years. #2nd biggest position for me a l-t hold " [X Link](https://x.com/DeepSouthDoctor/status/1867208467280269817) 2024-12-12T14:02Z [----] followers, [----] engagements "$KURA - With a market cap of $750m hard to believe it is now trading below cash levels (of $785m)- and they're in line to receive $420m in milestones in the next [--] quarters from their deal w KK. Welcome to biotech investing" [X Link](https://x.com/DeepSouthDoctor/status/1867287492703179096) 2024-12-12T19:16Z [----] followers, [----] engagements "@monaco_biotech $ETON is going to grind forward and I'm betting on them that they accomplish their longer-term goal of achieving a $1B market cap - roughly a triple from here. Fun to watch them execute" [X Link](https://x.com/DeepSouthDoctor/status/1869035659828363768) 2024-12-17T15:03Z [----] followers, [---] engagements "Re-bought $VKTX at $42.4 after selling at $51 two weeks ago. I've never owned them b/c I expect a buyout so today's (irrational) reaction to $MRK news seems like a decent buying/trading opportunity. Valuation is now much more reasonable" [X Link](https://x.com/DeepSouthDoctor/status/1869394489124725083) 2024-12-18T14:49Z [----] followers, [----] engagements "@Berlinergy $CMRX - My long-term price target is $12 which at current shares outstanding translates to a $1B market cap" [X Link](https://x.com/DeepSouthDoctor/status/1869803142982074866) 2024-12-19T17:53Z [----] followers, [---] engagements "$KURA now selling at a negative Enterprise Value of almost $100m. Irrational but such is life in biotech-land. Biotech indices now flat or negative for [----]. $KURA - With a market cap of $750m hard to believe it is now trading below cash levels (of $785m)- and they're in line to receive $420m in milestones in the next [--] quarters from their deal w KK. Welcome to biotech investing. $KURA - With a market cap of $750m hard to believe it is now trading below cash levels (of $785m)- and they're in line to receive $420m in milestones in the next [--] quarters from their deal w KK. Welcome to biotech" [X Link](https://x.com/DeepSouthDoctor/status/1869804730698084611) 2024-12-19T17:59Z [----] followers, [----] engagements "@ValueDig $AGIO $KURA $SNDX $VNDA" [X Link](https://x.com/DeepSouthDoctor/status/1870161922424807580) 2024-12-20T17:38Z [----] followers, [---] engagements "$ARWR - re-bought 50% position $19.50. Waiting to see if it goes (much) lower before buying full position. Had sold it profitably a month ago at $24 so the discount at today's price seems like a gift. Anyone else finding $ARWR interesting at $20. Lots of intriguing valuations now in micro/small-cap bios. Anyone else finding $ARWR interesting at $20. Lots of intriguing valuations now in micro/small-cap bios" [X Link](https://x.com/DeepSouthDoctor/status/1870178489866895712) 2024-12-20T18:44Z [----] followers, [----] engagements "Sold $VKTX again for minor trading profits. Just wanted to raise cash and like others better given what I consider their "catalyst desert" for the time being. As much as I like their data other companies have had plenty of time to consider/partner so not expecting it soon. Re-bought $VKTX at $42.4 after selling at $51 two weeks ago. I've never owned them b/c I expect a buyout so today's (irrational) reaction to $MRK news seems like a decent buying/trading opportunity. Valuation is now much more reasonable. Re-bought $VKTX at $42.4 after selling at $51 two weeks ago. I've never owned them b/c" [X Link](https://x.com/DeepSouthDoctor/status/1870179410000896462) 2024-12-20T18:48Z [----] followers, [----] engagements "$CMRX valuation is still super cheap IMHO. Today's extended credit line - untapped as yet - and potentials proceeds from a PRV put them in enviable position to launch 1st to market drug likely in Q3. Remains my #2 position and a long-term hold" [X Link](https://x.com/DeepSouthDoctor/status/1873745721540988956) 2024-12-30T14:59Z [----] followers, [----] engagements "$SNDX - bought more this morning. I think 1st to market mover advantage with mono tx. sub-group AML drug and likely 1st to market with combo regimens is the "catbird's seat". And launch of GvHD drug (note RoyPharm deal) seems largely ignored" [X Link](https://x.com/DeepSouthDoctor/status/1873747036274823505) 2024-12-30T15:04Z [----] followers, [----] engagements "@Nick09321587504 @JNap5C They will both release data and communicate how they plan to progress the drug (and the trials they run) going forward" [X Link](https://x.com/DeepSouthDoctor/status/1873816116046500178) 2024-12-30T19:39Z [----] followers, [--] engagements "2024 Biggest Wins: $ETON $CADL $XERS $CMRX $ACHV $CELC $VKTX [----] Biggest Losses: $CHRS $FULC $SCPH [----] Stats: Last [--] yrs. (Avg.) Me: + 47.2% + 30.3% XBI: + 0.9% + 05.4% NBI: - 1.4% + 05.7% RUT: + 10.0% + 06.4% S&P500: + 23.3% + 12.8% NASD: + 28.6% + 17.3% [----] Stats: Last [--] yrs. (Avg.) Me: + 47.2% + 30.3% XBI: + 0.9% + 05.4% NBI: - 1.4% + 05.7% RUT: + 10.0% + 06.4% S&P500: + 23.3% + 12.8% NASD: + 28.6% + 17.3%" [X Link](https://x.com/DeepSouthDoctor/status/1874791085018628314) 2025-01-02T12:13Z [----] followers, [----] engagements "Congrats to $NARI longs. Per usual it's crucial to "Buy low and Sell high" as stock was well over $100 [--] years ago with dips below $40 in past [--] months. Hoping that buyout is a good omen for overall Biotech market" [X Link](https://x.com/DeepSouthDoctor/status/1876632207172813226) 2025-01-07T14:09Z [----] followers, [---] engagements "@intimepk I think like any competent management team they will be open to all options (e.g. partner buyout or go it alone.) Personally I'd be surprised if they did try to completely commercialize it on their own" [X Link](https://x.com/DeepSouthDoctor/status/1876689499016569174) 2025-01-07T17:56Z [----] followers, [---] engagements "$ZNTL - Bought 20% more. Like the Investor Day announcement - pre-market on a Wed. - that will have lots of new data and presumably a clear future direction. With lots of cash and a huge negative EV love the risk/reward here" [X Link](https://x.com/DeepSouthDoctor/status/1877736269947494519) 2025-01-10T15:16Z [----] followers, [----] engagements "Some interesting names - some really solid micro/smid-cap biotechs - hitting 52-week lows: $ACHV $AVDL $CELC $DAWN $ETNB $GPCR $IOVA $KURA $URGN" [X Link](https://x.com/DeepSouthDoctor/status/1877763620378992677) 2025-01-10T17:05Z [----] followers, [----] engagements "I hope this trend of every biotech feeling compelled to release (mostly) non-newsworthy PRs on the first morning of JPM dies a quick death" [X Link](https://x.com/DeepSouthDoctor/status/1878807352461390141) 2025-01-13T14:12Z [----] followers, [---] engagements "$VKTX (No Position): Seems dead in the water until we get (closer to) new data from a new trial. Prospective partners have had lots of time to review existing data - and they're clearly not biting. Too short duration Ph2 oral might not move the needle much" [X Link](https://x.com/DeepSouthDoctor/status/1879567470245359802) 2025-01-15T16:33Z [----] followers, [----] engagements "$ZNTL: Not often you see a biotech with an Enterprise Value of negative $200m. A lot of recent volatility in the stock price even for small-cap biotech land. Hope to get a clear direction from management on Jan. 29th - incl. steps taken to reduce burn rate" [X Link](https://x.com/DeepSouthDoctor/status/1879977543639658614) 2025-01-16T19:42Z [----] followers, [----] engagements "$VKTX - When you look at valuations for $ALT $ETNB $GPCR $SGMT you realize that $VKTX could fall a lot more. Not saying all [--] companies should be valued similarly but none have an Enterprise Value of even $800m while $VKTX's current EV = $2.7B" [X Link](https://x.com/DeepSouthDoctor/status/1879978590751916375) 2025-01-16T19:46Z [----] followers, [----] engagements "@BioValues I am clueless. Remember for every seller there is a buyer. My assumption is the volatility has no meaning. I say that because I think of all the bios that traded down sharply 1-2 days prior to a significantly positive data release (and one recognized as such by the market)" [X Link](https://x.com/DeepSouthDoctor/status/1879991444586525166) 2025-01-16T20:37Z [----] followers, [---] engagements "$PRTA - bought 60% position last wk in low $13s hope to buy rest this wk at close to same price. Am bullish on SPA Ph3 in AL Amlydss - data due Q225 as well as potential of Ph012 in Alzhm to have strong data mid-year. Have [--] big Pharma deals for [--] lead drugs EV only $220m" [X Link](https://x.com/DeepSouthDoctor/status/1881720020906172795) 2025-01-21T15:06Z [----] followers, [----] engagements "Bought 60% position in $TARA past few days. EV is $0 company has Q2 data readouts in bladder cancer and lymphatic malformations with strong prior data. Ph3 data in IV choline chloride due YE25/Q126 offers great potential value too. Has enough cash to get to 2027" [X Link](https://x.com/DeepSouthDoctor/status/1884234835922936289) 2025-01-28T13:39Z [----] followers, [----] engagements "$PRTA - bought more to get to a "100%/typical-sized position". I like to buy on "Red" days. Will definitely be holding through Ph3 data readout in Q2. $PRTA - bought 60% position last wk in low $13s hope to buy rest this wk at close to same price. Am bullish on SPA Ph3 in AL Amlydss - data due Q225 as well as potential of Ph012 in Alzhm to have strong data mid-year. Have [--] big Pharma deals for [--] lead drugs EV only $220m. $PRTA - bought 60% position last wk in low $13s hope to buy rest this wk at close to same price. Am bullish on SPA Ph3 in AL Amlydss - data due Q225 as well as potential of" [X Link](https://x.com/DeepSouthDoctor/status/1886428418926944610) 2025-02-03T14:55Z [----] followers, [----] engagements "$IMCR - bought yesterday @ $30. Like the r/r here - esp. limited downside IMHO. While not my reason for buying I do see them as ideal candidate for a buyout as they own w/w rights to lead drug w nice sales (Q3=$80m) & true "pipeline in a product". Ph1 HIV data this Q a bonus" [X Link](https://x.com/DeepSouthDoctor/status/1887841705577095568) 2025-02-07T12:31Z [----] followers, [----] engagements "$CMRX - ditto [--] weeks later. Nice move today especially in the face of strong "red" day for biotech. $CMRX (my #2 holding) also making new 52-week highs on strong volume. Awaiting FDA acceptance this Q of filing for lead glioma drug with a launch & PRV in 2H25. Stock still quite cheap IMHO esp. with potential of Ph3 trials in 1L and 2nd-Gen prod that will read out Q3/Q2. $CMRX (my #2 holding) also making new 52-week highs on strong volume. Awaiting FDA acceptance this Q of filing for lead glioma drug with a launch & PRV in 2H25. Stock still quite cheap IMHO esp. with potential of Ph3 trials" [X Link](https://x.com/DeepSouthDoctor/status/1887919988436255013) 2025-02-07T17:42Z [----] followers, [----] engagements "$CELC: Re-bought full position ahead of pivotal Q2 data. Have traded profitably before but now planning to hold thru data" [X Link](https://x.com/DeepSouthDoctor/status/1888962330698162673) 2025-02-10T14:44Z [----] followers, [----] engagements "$CMRX - have a feeling below quote will be true again today with receipt of Priority Review Aug. PDUFA w no need for AdComm. If 1L trial is successful then stock will easily hit double digits. $CMRX (my #2 holding) also making new 52-week highs on strong volume. Awaiting FDA acceptance this Q of filing for lead glioma drug with a launch & PRV in 2H25. Stock still quite cheap IMHO esp. with potential of Ph3 trials in 1L and 2nd-Gen prod that will read out Q3/Q2. $CMRX (my #2 holding) also making new 52-week highs on strong volume. Awaiting FDA acceptance this Q of filing for lead glioma drug" [X Link](https://x.com/DeepSouthDoctor/status/1891845508798337499) 2025-02-18T13:41Z [----] followers, [----] engagements "@Biohazard3737 When is the last time a nano/micro/smid-cap biotech reacted well to a partnering deal $STOK joins recent list of declining price post-partnering news that includes $ARWR $KURA" [X Link](https://x.com/DeepSouthDoctor/status/1892797417872875837) 2025-02-21T04:44Z [----] followers, [----] engagements "$LRMR - bought 90% of a full position. Company trading at cash bullish on strong dose-dependent data to date for lead (only) drug with data updates coming mid-year" [X Link](https://x.com/DeepSouthDoctor/status/1894041385839235525) 2025-02-24T15:07Z [----] followers, [----] engagements "$DAWN - I don't see it as undervalued. EV/prod revenue projection for [----] = [---]. Got way ahead of itself when trading in high teens. Hopefully a growth story for years but seems fairly valued now" [X Link](https://x.com/DeepSouthDoctor/status/1894847355158941979) 2025-02-26T20:29Z [----] followers, [----] engagements "@niubi1988 No longer follow $CRNX (b/c I thought it was so overvalued) so hard to say. $DAWN probably a safer bet though" [X Link](https://x.com/DeepSouthDoctor/status/1895130735360541129) 2025-02-27T15:15Z [----] followers, [---] engagements "Red days are for buying Re-bought half position in $ARWR (at 10%+ discount from last time I sold it). I'd prefer to patiently hold it long-term because the company has so many "ways to win". We shall see. Current positions in order of size: $ETON $CMRX $PTGX $URGN $LRMR $TARA $CELC $ACHV Considering for next Buys: $ARWR $CGEM $DERM $GPCR $HRMY $PRTA $RCKT Current positions in order of size: $ETON $CMRX $PTGX $URGN $LRMR $TARA $CELC $ACHV Considering for next Buys: $ARWR $CGEM $DERM $GPCR $HRMY $PRTA $RCKT" [X Link](https://x.com/DeepSouthDoctor/status/1896578821832540665) 2025-03-03T15:10Z [----] followers, [----] engagements "$CMRX - pretty impressive that it continues to make new 52-week highs given desultory overall biotech sector performance of late. Con't to believe that stock still has a lot of upside with multiple catalysts Q2/Q3" [X Link](https://x.com/DeepSouthDoctor/status/1896600724911620375) 2025-03-03T16:37Z [----] followers, [----] engagements "$PTGX - Home run Ph3 PV data. Am more confident that Ph3 psoriasis data in Q2 will be good. Silly to sell this on a red day for biotech. Expecting a move up to mid-40s soon. See Ph2b UC trial as most iffy but w higher upside impact if good data than downside risk w failure" [X Link](https://x.com/DeepSouthDoctor/status/1896616681432310091) 2025-03-03T17:40Z [----] followers, [---] engagements "Screw it - bought more $ARWR now at full-sized position with entry at avg. of $18" [X Link](https://x.com/DeepSouthDoctor/status/1896657846626128201) 2025-03-03T20:24Z [----] followers, [----] engagements "Swapped $PTGX for $PRTA view the latter as more undervalued. Still very bullish on former in general but least excited by data readout in UC this Q. $PRTA with SPA Ph3 data in Q2 w upside bonus of Ph1 Alz data mid-25" [X Link](https://x.com/DeepSouthDoctor/status/1896938724245860803) 2025-03-04T15:00Z [----] followers, [----] engagements "$ALT $GPCR $SGMT $VKTX - [--] sisters all dressed up at the big obesity/MASH gala and nobody is asking them to dance" [X Link](https://x.com/DeepSouthDoctor/status/1896947160127856833) 2025-03-04T15:33Z [----] followers, [---] engagements "$TCMD: Bought full position yesterday. Boring growth story company profitable enuf cash to fund share buyback. EV/product revenue is less than [---] so super cheap IMHO. Nice way to diversify from trial outcome-driven bios" [X Link](https://x.com/DeepSouthDoctor/status/1897651911437754628) 2025-03-06T14:14Z [----] followers, [----] engagements Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing
@DeepSouthDoctor Keith Abrams
Keith Abrams posts on X about bullish, $urgn, $tcmd, $hrmy the most. They currently have [-----] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours.
Engagements: [-----] #
- [--] Week [-----] +424%
- [--] Month [------] +40%
- [--] Months [-------] +34%
- [--] Year [-------] +48%
Mentions: [--] #
- [--] Month [--] +55%
- [--] Months [---] +56%
- [--] Year [---] +92%
Followers: [-----] #
- [--] Week [-----] no change
- [--] Month [-----] +1.30%
- [--] Months [-----] +6.60%
- [--] Year [-----] +14%
CreatorRank: [---------] #
Social Influence
Social category influence finance stocks cryptocurrencies technology brands countries social networks currencies
Social topic influence bullish, $urgn #4, $tcmd #1, $hrmy #1, $vktx, $crvs #18, longterm, data, $abeo #2, $rzlt
Top accounts mentioned or mentioned by @jfais20 @semodough @avidresearch @monacobiotech @bokhzam @blasebio @buylowersellhih @chrisolin @berlinergy @andreagtc @mbbiotech @aamortazavi @jamesekrause @bradloncar @mathcoredad @oldgraperx @stockkhoj @shoshinvalue @jnap5c @sharkbiotech
Top assets mentioned Harmony Biosciences Holdings, Inc. (HRMY) Viking Therapeutics, Inc (VKTX) Prothena Corporation plc Ordinary Shares (PRTA) Arrowhead Research Corporation (ARWR) Iovance Biotherapeutics, Inc. Common Stock (IOVA) Vir Biotechnology, Inc. Common Stock (VIR) Rainmaker Games (RAIN) Soleno Therapeutics, Inc. Common Stock (SLNO) IDEAYA Biosciences, Inc. Common Stock (IDYA) Axsome Therapeutics, Inc (AXSM) Celcuity Inc. Common Stock (CELC) Structure Therapeutics Inc. (GPCR) Protagonist Therapeutics, Inc (PTGX) Taraxa (TARA) Vera Therapeutics, Inc. (VERA) Kymera Therapeutics, Inc. (KYMR) Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) Apellis Pharmaceuticals, Inc. Common Stock (APLS) Ocular Therapeutix, Inc. (OCUL) Mirum Pharmaceuticals, Inc. Common Stock (MIRM) Seagen Inc (SGEN) Day One Biopharmaceuticals, Inc. (DAWN) Inari Medical, Inc. (NARI) Mineralys Therapeutics, Inc. (MLYS) Kyverna Therapeutics, Inc. (KYTX) Agios Pharmaceuticals, Inc. (AGIO) Arcutis Biotherapeutics, Inc. (ARQT) LianBio (LIAN) LYRA (LYRA) Cullinan Management, Inc. (CGEM) Xenon Pharmaceuticals Inc (XENE) TG Therapeutics, Inc. (TGTX)
Top Social Posts
Top posts by engagements in the last [--] hours
"$MLYS: That's what I wanted to see Mineralys Therapeutics Announces Positive Topline Results from Phase [--] Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria $MLYS: Re-bought full position ahead of imminent Ph2 hypertension/CKD readout. Am thinking data should be positive building on prior Ph3 success. While not my rationale for buying I do think company is a plausible takeout candidate. $MLYS: Re-bought full position ahead of imminent Ph2 hypertension/CKD readout. Am thinking data should be positive building on prior Ph3 success. While not"
X Link 2025-06-17T13:18Z [----] followers, [----] engagements
"$MLYS - Bought full position $32. Company filed YE - earlier than previously advertised - for best-in-class hypertension drug awaiting Ph2 data this Q in 2nd indication. Plenty of cash over 30% off of 52-week highs"
X Link 2026-01-21T14:20Z [----] followers, [----] engagements
"$ESPR - sold entire position for negligible loss. I've run out of patience was unhappy with both size of quarterly loss as well as rate of accelerated sales (and eventual peak sales). You know you're in trouble when ER doesn't mention net product sales in 1st paragraph"
X Link 2024-11-07T16:47Z [----] followers, [----] engagements
"Biotech giveth ($CADL $CMX) and taketh ($CRVO) away this week. Crazy week for my portfolio"
X Link 2024-12-11T14:27Z [----] followers, [---] engagements
"@RichardTip17589 No thoughts have never followed them. Will take a quick look though thanks for the name"
X Link 2025-08-06T19:46Z [----] followers, [---] engagements
"$BCRX: Read the CC transcript re: $ATXS deal. If Ph3 LAI drug is approvable (data Q127) I like the deal. Company est. [----] $1B cash balance $1B+ revenue (going to $1.8B in 2033). Early pipeline and possible add'l future BD a potential bonus. All in all it's a solid l-t buy"
X Link 2025-10-15T12:50Z [----] followers, [----] engagements
"$SLNO - Has handily beaten analyst estimates in all [--] Qs since Vykat launch in PWS Q225. Seemingly clearly on path for $1B+ in sales. Company bought back stock at higher levels profitable has $500m cash as of YE for possible acquisitions. Story seems increasingly bullish"
X Link 2026-01-12T13:25Z [----] followers, [----] engagements
"$SLNO - for all of the progress below stock trading near 52-week lows at $43 - and last secondary in July [----] went for $85. Seems like plenty of room to run not to mention potential for a "bolt-on acquisition" that would be immediately accretive to earnings for $SLNO - Has handily beaten analyst estimates in all [--] Qs since Vykat launch in PWS Q225. Seemingly clearly on path for $1B+ in sales. Company bought back stock at higher levels profitable has $500m cash as of YE for possible acquisitions. Story seems increasingly bullish. $SLNO - Has handily beaten analyst estimates in all [--] Qs since"
X Link 2026-01-12T13:31Z [----] followers, [----] engagements
"1H YTD= + 32% Top Winners: $CMRX $ATYR $VERA $RZLT $RIGL $RCKT $ABEO Top Losers: $PRTA $CRVO $LRMR $TCMD"
X Link 2025-07-01T13:10Z [----] followers, [----] engagements
"$AVBP - sold for a 4% loss. Upon re-reviewing the company am a little less bullish on Q126 Ph3 data and I simply like something else better"
X Link 2025-09-09T13:22Z [----] followers, [----] engagements
"One potential edge amateurs (like me) can have in biotech is finding unfollowed companies - then having the courage of your convictions. Most of my biggest wins past [--] months have been made that way (e.g. $CMRX $ETON $RZLT $TCMD $XERS) even though I sold some too early"
X Link 2025-11-04T14:10Z [----] followers, [----] engagements
"$ARQT - for a commercialization stage SMID-cap bio they are by far the most "expensive" via the EV/prod revenue screen - [---] based on [----] estimates. There is a difference between a great company and its valuation. Congrats to those who enjoyed the ascent but . . "
X Link 2025-11-24T16:12Z [----] followers, [----] engagements
"Portfolio Update/Current Positions in order of size: $TCMD $RZLT $IDYA $QNCE $URGN $TECX $KYTX $BCRX $AGIO Don't anticipate making any changes this month (unless a stock craters)"
X Link 2025-12-05T14:20Z [----] followers, [----] engagements
"$KYMR - That was predictable. They should raise at this valuation. Will be interested in the offering price. https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-announces-proposed-public-offering-2 $KYMR - I'll be very surprised if they don't raise in the next [--] hours. They should b/c I think their valuation is awfully high. https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-announces-proposed-public-offering-2 $KYMR - I'll be very surprised if they don't raise in the next [--] hours. They should b/c I think their valuation"
X Link 2025-12-08T21:08Z [----] followers, [----] engagements
"$TCMD keeps grinding higher sets new 52-week high today in sluggish market. Nothing sexy just an excellent growth story. My #1 position due to outsized gains (basis $10). $TCMD - Love that after initial profit-taking this morning stock con't to move up adding to recent impressive gains. [----] analyst consensus earnings estimates have risen. Really liked what I heard on the CC. Now fighting with $RZLT as a co-#1 position among my holdings. $TCMD - Love that after initial profit-taking this morning stock con't to move up adding to recent impressive gains. [----] analyst consensus earnings"
X Link 2025-12-10T15:55Z [----] followers, [----] engagements
"@jfais20 @Kapstahoon Doing initial DD on $AARD. What red flags are you seeing/most concerned about"
X Link 2025-12-12T19:16Z [----] followers, [---] engagements
"2025 performance was +77.5% but still made lots of mistakes. Big Wins: $CMRX $TCMD $URGN $QNCX $IDYA $ATYR Big Losses: $PRTA $VYNE $CRVO Biggest Regrets: $RZLT (not selling more pre-data) $CELC (selling all pre-data) $NKTR (not buying at lows) $ARWR (lack of patience)"
X Link 2026-01-02T14:15Z [----] followers, [----] engagements
"Current positions by size: $TCMD $TECX $IOVA $URGN $VIR $AVBP $CRVS $GUTS Sold $QNCX $KYTX $ABEO for sizable s-t profits. $GUTS - like their data more due Q1/Q2/Q3. $AVBP - re-bought on weakness Ph3 data due Q1. $VIR - added more love the r/r. Ph1b data this month"
X Link 2026-01-07T14:25Z [----] followers, [----] engagements
"$SPRB - bought at $77. Like the non-dilutive financing and I think the stock moves upward if/when they file their NDA this Q and more so if/when accepted by FDA. Company has BTD and is eligible for a PRV which is worth 1.5x current market cap"
X Link 2026-01-08T16:18Z [----] followers, [----] engagements
"Bought $XENE $41. Stock price got way ahead of itself 4-5 years ago after stellar Ph2b data but now couldn't be more bullish about upcoming Ph3 readout (in March) that is likely a best-in-class drug for a large TAM. Would expect "the next leg up" after positive results"
X Link 2026-01-14T15:53Z [----] followers, [----] engagements
"@jfais20 Per your "cage match" thinking there are several other commercial-stage bios that I think are far "cheaper"/ represent better value than $URGN - short list includes: $ABEO $BCRX $HRMY $IOVA $KURA $PLX $TCMD"
X Link 2026-01-15T00:00Z [----] followers, [----] engagements
"@avidresearch Atopic Derm is becoming more crowded in general (e.g. $CLDX $KYMR). No sense in me speculating (any more) about how $CRVS data stacks up - we'll find out Tuesday morning"
X Link 2026-01-17T05:01Z [----] followers, [----] engagements
"@anthonystaj @avidresearch If either of you haven't yet watched Brad Loncar's "Biotech TV" interview with Brian Skorney about $XENE here is the link below. https://www.biotechtv.com/post/brian-skorney-january-12-2025 https://www.biotechtv.com/post/brian-skorney-january-12-2025"
X Link 2026-01-17T16:14Z [----] followers, [---] engagements
"$SLNO - sold for penny profits. Just like others better wanted to raise cash and the market seems pretty blas about the stock these days"
X Link 2026-01-20T16:31Z [----] followers, [----] engagements
"Shorted my 1st biotech of [----]. Never hold shorts for very long just one way of hedging against a frothy market. Hint - I shorted them last month at a considerably higher price took decent profits quickly but way premature. Although to be fair I put profits to good use"
X Link 2026-01-22T18:32Z [----] followers, [----] engagements
"@AAMortazavi All you have to do is look at my last [--] weeks of tweets. $KYMR"
X Link 2026-01-22T18:38Z [----] followers, [---] engagements
"$VIR - up 25% this week on no news. You never know when (perceived) undervalued stocks begin to move up. Of course a much anticipated catalyst is coming up late next month but stock's recent strength is noteworthy. I remain long and holding"
X Link 2026-01-23T16:21Z [----] followers, [----] engagements
"@ZwerBio I appreciate the perspective especially. b/c I don't follow $JANX. However I don't think their partnering news explains $VIR strength all week or the magnitude of their increase"
X Link 2026-01-23T17:00Z [----] followers, [---] engagements
"$CRVS - bought back a chunk on the "mini-dip". While happy to buy back these shares at lower that what I last sold - remember I also sold some in the teens - I mainly want to direct more funds to bios that I feel are super solid - both with data trial design & management"
X Link 2026-01-30T17:06Z [----] followers, [----] engagements
"$AVBP - bought full position $21 past two trading days. May be a bit early but am bullish on Ph3 readout (Q126) in Exon20 nsclc and like other trials as well. 9% Insider ownership nice to see"
X Link 2025-07-28T13:05Z [----] followers, [----] engagements
"$EOLS - sold yesterday for a sizable loss. I will con't to follow them as I think they might turn things around by Q4 - supposedly 1st profitable quarter - or Q126 but they've clearly lost the confidence of investors given significant under-performance past [--] quarters"
X Link 2025-08-07T12:55Z [----] followers, [----] engagements
"Most of the Commercialization-stage bios that I follow (and generally like) are down YTD and down significantly from their 52-week highs despite biotech indices being up YTD and after a strong Q425. $ABEO $BCRX $CRMD $EOLS $ETON $HRMY $HROW $IOVA $OCUL $RIGL $SLNO $TARS $URGN"
X Link 2026-01-24T23:24Z [----] followers, [----] engagements
"Holding several bios w major Q1 data catalysts: $IDYA $IOVA $MYLS $OCUL $VIR Holding $SPRB w Q1 catalyst of filing sNDA YTD I'm 1-1 on major catalysts. Thankfully $CRVS gain $GUTS loss. Still holding $TCMD $TECX $CRVS Will re-evaluate $CRMD after Feb10 Analyst Day"
X Link 2026-02-06T19:54Z [----] followers, [----] engagements
"@BlaseBio They're way too small of a company to commercialize on their own a drug that would be primarily prescribed by Primary Care docs. It's one thing to sell a rare disease drug or one marketed to specialists but $MLYS is right to look for a partner"
X Link 2026-02-08T05:32Z [----] followers, [---] engagements
"Red days are for buying. Bought full position last few days in $PVLA Re-bought full position in $XENE this morning. Both with Ph3 readouts next month very bullish on both"
X Link 2026-02-11T15:01Z [----] followers, [----] engagements
"@binarypharmer I prefer $MGDL over $VKTX. No substitute for their much larger Ph2b done in actual NASH population"
X Link 2018-12-06T15:56Z [----] followers, [--] engagements
"I've been following $CCXI for a long time (and am a definite bull). IMO the Q3 earnings call transcript lays out the case for Avacapan better than any previous talks/presentations. Encourage bioinvestors to read the transcript via SA"
X Link 2019-11-05T14:29Z [----] followers, [--] engagements
"@lblegend33 @Miljenkoz @65 People are waiting for them to make a statement about to what extent the Ph3 trial might be delayed. Too the short-term attention span of (biotech) investors means $MGDL will still likely be a bargain more than a year from now. Meantime remember the raises at $305 and $108"
X Link 2020-04-01T17:38Z [----] followers, [--] engagements
"$ONCT was at $1.7 at the end of Q320. Since that time they really haven't released significant new data. Now it has gone up more than 5x. Biotech can be a funny game. Bought $ONCT past two days. For a micro-cap bio they have [--] different Ph1/2 data set readouts this quarter. Already have excellent preliminary data in MCL good data in CLL and just nabbed a RPDD for 3rd indication in r/r Ewing's Sarcoma. All that & an EV $25m Bought $ONCT past two days. For a micro-cap bio they have [--] different Ph1/2 data set readouts this quarter. Already have excellent preliminary data in MCL good data in CLL"
X Link 2021-03-17T14:30Z [----] followers, [--] engagements
"It is beyond me to understand why $CLRB has an EV of $15m with their pipeline data and balance sheet"
X Link 2021-05-15T16:56Z [----] followers, [--] engagements
"Bought some $EIGR. Don't know if it (and $MGDL $EYEN) are suffering by association with $MIST but $EIGR's lead drug is for HepD where there are no approved txs. Ph3 data coming this Q - it's not a slam dunk but am pretty bullish and has BTD/PRIME status"
X Link 2022-10-19T17:45Z [----] followers, [--] engagements
"$RAIN strong of late on unusually robust volume. Given that 52-week high is $16 and my bullish view of Ph3 trial prospects content to hold thru Q123 data. Re-established position (thankfully able to buy more shares) in $RAIN $6 ahead of pivotal Q123 readout. Would like to add even a few more shares if it re-traces a bit. Still seems to be flying under the radar with very low volume (except for today). Re-established position (thankfully able to buy more shares) in $RAIN $6 ahead of pivotal Q123 readout. Would like to add even a few more shares if it re-traces a bit. Still seems to be flying"
X Link 2022-11-22T16:41Z [----] followers, [--] engagements
"Current holdings in order of weighting: $BTAI $ZYME* $PRVB $RAIN# $TSHA# $PHAT# $XFOR* $EIGR* $AUTL* * = Q4 data readouts # = Q123 data readouts $BTAI & $PRVB I just still like on a valuation basis even after significant appreciation from cost basis"
X Link 2022-11-29T16:45Z [----] followers, [--] engagements
"$MGDL is the latest example of a stock really taking off based on trial data because the Ph3 and/or binary to the company results clearly exceeded "Street" expectations. See $AUPH $CCXI in years past (and on a % basis they appreciated more). Congrats to $MDGL longs"
X Link 2022-12-21T14:06Z [----] followers, [----] engagements
"$RAIN - sold 50% of my shares at 95% profit. Remain bullish on (binary) Ph3 readout but seemed prudent to take some money off the table. Looking forward to data readout this Q"
X Link 2023-01-10T15:22Z [----] followers, [----] engagements
"Current positions in order of $$: $BTAI $ZYME $LIAN $MIRM $PHAT $GTHX $ACHV $PRAX 1st [--] choices are longer-term holds latter [--] geared to near-term data catalysts or w ith $PHAT clarity w FDA). Want to buy back $PRVB $RAIN at right price $TCON when I can avoid "wash loss""
X Link 2023-01-11T16:32Z [----] followers, [----] engagements
"$PRAX now up 55% on [---] million share volume (avg. daily volume = 464K). Wonder who is driving the volume"
X Link 2023-01-13T15:22Z [----] followers, [----] engagements
"Re-bought $RAIN at $9.80 after selling last week at $12.84. Fundamentals remain the same am bullish on the Ph3 trial that reads out this Q. Happy to take advantage of stock price volatility"
X Link 2023-01-17T15:05Z [----] followers, [----] engagements
"$RAIN with big move today on huge volume. I guess somebody else is bullish about imminent Ph3 data"
X Link 2023-02-10T16:20Z [----] followers, [----] engagements
"Unusual play for me but bought $SGEN. Buyout price (all cash offer) is 16% above current price deal to close around YE23. A lot better than any money market happy to park some funds there. (And there is always a slight chance another suitor comes along w better offer.)"
X Link 2023-03-14T13:45Z [----] followers, [----] engagements
"Top [--] biotechs trading at greater than a negative $100m EV: $LIAN (long) $CMRX $KRON (no position in latter 2). In my view legit companies with real pipelines and story. I welcome additions to the list"
X Link 2023-03-17T13:47Z [----] followers, [----] engagements
"Interesting stock price action in $ALT and $SELB. Don't follow either closely but stocks are way down on heels of seemingly decent data readouts. Obviously they don't put all relevant info into the PR - or were expectations just out of whack"
X Link 2023-03-21T14:09Z [----] followers, [----] engagements
"Q123 Portfolio update: Biggest winners: $PRVB $ACHV $RAIN $ZYME Biggest losers: $GTHX $TSHA $PRAX Current holdings in order of size: $ACHV $BTAI $AXSM $LIAN $RAIN $XERS $MRSN $PDSB $XFOR $PHAT $SRTS Portfolio Update: (I only buy/sell long positions in micro-cap SMID-cap biotechs no shorting no options). Q123 performance: up 58% vs. S&P500 (+7%) NBI (-2%) XBI (-7%) YE16 to YE22 Last [--] full yrs Annual Average Performance: Up 31% vs. XBI (+ 6%) NBI (+ 7%) Portfolio Update: (I only buy/sell long positions in micro-cap SMID-cap biotechs no shorting no options). Q123 performance: up 58% vs. S&P500"
X Link 2023-04-03T13:17Z [----] followers, [----] engagements
"Q223/Q323 Ph3 data catalysts I am watching closely: $ACHV* $APLT $AXSM* $BTAI* $CBAY $CRNX $LIAN* $MIRM $MRSN* $RAIN* $TVTX $XFOR* * = I am long Am bullish on all the ones I own plus $CRNX lukewarm on $MIRM prefer to be on sidelines for others"
X Link 2023-04-03T13:23Z [----] followers, [----] engagements
"Current positions in order of size: $SGEN $BTAI** $ACHV** $AXSM** $XERS $XFOR** $MRSN** $ASLN** $RAIN** $SRTS $ARAV** ** = key Ph2b or Ph3 data either Q223 or mid23 ($MRSN $ARAV). Am treating $SGEN like a high-yield money market acct. Eyeing $CHRS post Q1 earnings call"
X Link 2023-05-02T14:55Z [----] followers, [----] engagements
"Re-sold $RAIN for minor profits (after huge gains in Q1). At $10+ R/R is a tossup and want to take a final more detached re-assessment of Ph3 data prospects this Q. Too having a huge year (+ 120% YTD) & likely volatility w debt crisis make me want to build up cash reserves"
X Link 2023-05-17T16:12Z [----] followers, [----] engagements
"@JamesEKrause See Brad Loncar's @bradloncar TV" interview with $SGEN CEO. Brad saves it for the last question of the interview"
X Link 2023-06-05T15:05Z [----] followers, [--] engagements
"@BoitechB @JamesEKrause @bradloncar The $SGEN CEO said he absolutely expects a 2nd request"
X Link 2023-06-05T19:23Z [----] followers, [--] engagements
"$DAWN -- (Part 1) It's fair to debate what is a reasonable valuation here - and how one arrives at it. I have little doubt that Tovo is approved mid-24 but signf sales not till 1H25 w reimbursement timelines. Ph3 1L LGG data not till 2H25 so 2nd appr indic not till YE26"
X Link 2023-06-11T17:18Z [----] followers, [----] engagements
"$DAWN (Part 2) Stock price has gone from My'21 IPO @ $16 to Jn'22 raise at $16 to Jn'23 raise @ $13. Current MC=$1.06B w post-raise cash of $460m. They can sell RPDD voucher but will burn $40m+ each Q for next few years. I never assume a b/o. So PT & evaluation method $DAWN -- (Part 1) It's fair to debate what is a reasonable valuation here - and how one arrives at it. I have little doubt that Tovo is approved mid-24 but signf sales not till 1H25 w reimbursement timelines. Ph3 1L LGG data not till 2H25 so 2nd appr indic not till YE26 $DAWN -- (Part 1) It's fair to debate what is a reasonable"
X Link 2023-06-11T17:24Z [----] followers, [----] engagements
"$MRSN: Had sold for profits b/c I thought valuation was too high skewing risk/reward. Am very surprised though by today's news. Taking profits and/or avoiding big losses (see prior tweets on $RAIN) is as important to portfolio management as identifying big winners. Bought $MRSN past few trading days. Am bullish on Ph3 UpRi trial in PROC reporting mid-23 (and they want a Euro partner) w add'l trials ongoing GSK option (after already paying $100m upfront) for [----] & research deals w JAN MRK that yielded $70m cash $1.8B+ milestones. Bought $MRSN past few trading days. Am bullish on Ph3 UpRi"
X Link 2023-06-15T15:11Z [----] followers, [----] engagements
"Current positions in order of size: $SGEN $BTAI $XERS $PDSB $XFOR $ACHV $CHRS $KALV $GRTX $ASLN Surprised that $ASLN seemingly flying under the radar w Ph2b data in modr-svr atopic derm coming early July. $BTAI $XFOR have near-term data readouts $GRTX PDUFA date as well"
X Link 2023-06-15T17:26Z [----] followers, [--] engagements
"Added to $CHRS today. Long-term hold. Will be interesting to see $SURF's updated data this month for their lead candidate. Like CHRS's efforts to diversify projected near-future revenues"
X Link 2023-06-16T13:41Z [----] followers, [--] engagements
"@mathcoredad I give 'em credit for bolstering their biosim portfolio (Eylea) and d/c'ing one they felt wasn't going to pan out. Kudos too for diversifying beyond biosims. While any cancer drug in dev'l is a likely eventual fail $SURF's pipeline comes cheap. And I love Topi's data to date"
X Link 2023-06-17T05:22Z [----] followers, [--] engagements
"@arkabagchi24 I sold $RAIN before Ph3 results came out (and made a lot of money on them earlier). I've also sold $ARAV. Tweeted about both decisions at the time"
X Link 2023-06-24T04:46Z [----] followers, [--] engagements
"Re-bought $MIRM for a few cents more from where I sold in April. Like the synergistic purchase of $TVTX products and like their chances for significant results for their [--] Q4 Ph2/3 trials. I never anticipate a b/o but always liked them much more than $ALBO"
X Link 2023-08-03T15:39Z [----] followers, [----] engagements
"$LYRA: Also on sidelines pre-Ph2 [---] data. From what I can extrapolate very dicey to predict magnitude of effect (vs. plcb) N = only [--] per cell & not using best PE measure. Conversely I am bullish on Ph3 [---] w data Q224 and I do see stock as pretty cheap at these levels"
X Link 2023-09-05T13:15Z [----] followers, [----] engagements
"$MIRM with [--] Ph2/3 readouts due Q423 + a Dec. PDUFA date for 2nd indication for Livmarli is up strong on a day when the biotech & small-cap markets are down. Acquisition of $TVTX products provide add'l downside protection while upside is quite significant if trials succeed"
X Link 2023-09-05T17:38Z [----] followers, [----] engagements
"$SNDX has been making new 52-week lows daily for the past week or so in advance of (supposedly) Q3 Ph3 data readout in acute leukemia. Will be interesting to see how this plays out. (I have no position b/c I am not enthusiastically bullish about Ph3 prospects.)"
X Link 2023-09-29T14:07Z [----] followers, [----] engagements
"@jfais20 In general yes. However $CHRS management has been clear that Yusimry uptake will be much slower with different issues related to gaining market share. ($CHRS is my #1 holding.)"
X Link 2023-10-04T16:49Z [----] followers, [---] engagements
"@OldgrapeRX You are leaving out Eylea biosim launch in Q225 will be a significant contributor to revenue ultimately likely their biggest revenue producer"
X Link 2023-11-07T15:56Z [----] followers, [---] engagements
"Bought $MOR. I don't get hyper-focus on 2nd endpt. of TSS50. Very confident Ph3 (data end of Nov. then oral talk at ASH) hits the sole PE think it hits on most secondaries and "totality of data" will clearly be SOC AND approvable. Buying when others run to the exits"
X Link 2023-11-17T15:16Z [----] followers, [----] engagements
"Sold $MOR into strength for small profit. Sell-off after initial data release was excessive nice to see stock recover going into ASH presentation. Bought $MOR. I don't get hyper-focus on 2nd endpt. of TSS50. Very confident Ph3 (data end of Nov. then oral talk at ASH) hits the sole PE think it hits on most secondaries and "totality of data" will clearly be SOC AND approvable. Buying when others run to the exits. Bought $MOR. I don't get hyper-focus on 2nd endpt. of TSS50. Very confident Ph3 (data end of Nov. then oral talk at ASH) hits the sole PE think it hits on most secondaries and"
X Link 2023-11-30T15:00Z [----] followers, [----] engagements
"Bought back into $SGEN at $213.00. Seems like a good place to park cash. Expecting PFE takeover at $229 to go through by YE23 or early Q124"
X Link 2023-11-30T16:24Z [----] followers, [----] engagements
"Bought $CLRB last week. Am bullish on their Ph3 readout coming up at JPM in [--] weeks. Conversely am aghast at history of [--] reverse splits over past [--] yrs. I do think their lead drug is active though w low bar for success in indication w/o an approved tx"
X Link 2023-12-11T14:19Z [--] followers, [----] engagements
"$KALV - went from early morning red to big green move on strong volume. Con't to hold thru early Q1 Ph3 data for on-demand HAE tx. Very bullish on trial"
X Link 2023-12-11T20:47Z [----] followers, [---] engagements
"That worked out well. Doesn't make up though for selling $MOR (into strength) too early. Not many boring days in biotech. Bought back into $SGEN at $213.00. Seems like a good place to park cash. Expecting PFE takeover at $229 to go through by YE23 or early Q124. Bought back into $SGEN at $213.00. Seems like a good place to park cash. Expecting PFE takeover at $229 to go through by YE23 or early Q124"
X Link 2023-12-12T18:37Z [--] followers, [----] engagements
"$ACHV: Listened to CEO's interview at Life Science Forum. Of course he said they were blindsided by FDA request for l-t safety data. Topic of company balance sheet was blithely ignored. They want/expect to have a w/w part on board by Q224. If so they'll be fine. If not . . "
X Link 2023-12-15T14:20Z [----] followers, [----] engagements
"$ACRS: Mixed feelings about corporate update. However company (at $0.80) has a $59m market cap with a $202m cash balance and a reduced burn rate going forward. So surprised downside move is so strong expect it to bounce a bit from this level"
X Link 2023-12-20T14:38Z [----] followers, [----] engagements
"2023 Stats Part 2: I owned [--] different bios in [----] profited in [--] (61%). Biggest Winners: $PRVB $RAIN $MIRM Biggest Losers: $GRTX $GTHX Sold too Soon: $CBAY $CRNX $LIAN"
X Link 2024-01-02T14:03Z [----] followers, [----] engagements
"$CHRS: Listened to the call this a.m. I applaud the transaction - they leveraged their strengths (e.g. higher margin products Loqtorzi & Casdozo data) and shored up their weaknesses (e.g. balance sheet). Potential future deals await (e.g. selling Yusimri ex-USA partners)"
X Link 2024-01-22T16:32Z [----] followers, [----] engagements
"$CHRS: At current price stock selling for well 2x [----] proj. revenues w much improved balance sheet. Is the primary perception negative that they've mostly failed w their biosimilars or positive that they've nimbly pivoted/narrowed their focus aided by shrewd deal-making"
X Link 2024-01-22T18:49Z [----] followers, [----] engagements
"@sunrgu Yeah lots of moving parts here. I don't think investors will get a really clear view until maybe the Q124 or even Q224 earnings call - [--] months after Loqtorzi launch deal closure headcount reduction planned add'l oncology trials potential add'l partnering or co-dev'l deals"
X Link 2024-01-22T19:55Z [----] followers, [---] engagements
"@IvanmacMac Even if they beat estimates still seems overvalued to me. And next pipeline products are only in Ph2a"
X Link 2024-01-29T16:25Z [----] followers, [--] engagements
"@ZbJohnson124 Of the ones I follow closely - $LYRA $NARI $PHAT"
X Link 2024-02-12T16:36Z [----] followers, [---] engagements
"@drobne9 I probably won't hold them long-term but I don't expect to settle for a loss either so let's see how the Q4 earnings call goes"
X Link 2024-02-14T00:00Z [----] followers, [--] engagements
"$SWTX: I dont' understand the valuation. Launched 1st drug YE23 now w an EV over $3B. Who'd pay a premium to that to buy them out Projected [----] sales are $65m. How does one account for current valuation Sign to me that in places biotech market is getting quite frothy"
X Link 2024-02-16T19:04Z [----] followers, [----] engagements
"@meraghumittal M & A almost not mentioned at all. While I trust management's acumen to make a sound acquisition I don't see it occurring until Q4 at earliest b/c I think Ph2 data/Ph3 requirements and commercial performance of products are needed to clarify how to allocate $ going forward"
X Link 2024-03-06T18:57Z [----] followers, [---] engagements
"$CHRS: Listened to earnings call. Best tidbit: Loqtorzi is predicted to reach peak sales of $200m in its initial indication in [--] 1/2-3 years. Along with Udencya's increased market share con't to ramp up seems clear that they will achieve sustained profitability from 1H25"
X Link 2024-03-14T01:41Z [----] followers, [----] engagements
"@bio_report We won't really get a true picture until the Q2 earnings call - and analysts like to be spoon-fed guidance. However company has made several moves to reduce expenses"
X Link 2024-03-14T03:08Z [----] followers, [--] engagements
"$NARI making new 52-week lows not getting any love from the market. A bit puzzled as to why but no mistaking the trend"
X Link 2024-03-15T16:05Z [----] followers, [----] engagements
"$SGMT: I'm a buyer here. Stock was at $6.50 before release of Ph2b NASH data. Stock zooms to $18+ post Jan 22nd data release. Retraces a bit next [--] days as they do a raise at $12.50. Now stock at $4.10 on no subsequent news. MC=$132m Cash=$208m no debt. Go figure"
X Link 2024-03-18T13:44Z [----] followers, [----] engagements
"Based on formula below of the bios I follow I come up with: Great Value: $CHRS $ESPR $AUPH $ETON (i.e. EV/prod rev = [---] profitability in [----] and/or [----]. Good/Fair Value: $ACAD $HROW $XERS $CPRX $RVNC $NARI Poor Value: $PHAT $TGTX $TARS $ARQT Valuation food for thought: I rate micro/smid-cap bios using the formula: EV divided by FY24 product revenue. Same for FY25 product revenue. EV = market cap + debt minus cash plus/minus FY burn rate/profitability rate. This formula doesn't assess pipeline or growth rate. Valuation food for thought: I rate micro/smid-cap bios using the formula: EV"
X Link 2024-03-25T12:59Z [----] followers, [----] engagements
"@OldgrapeRX @Dreesenkl Think of the formula I proposed as a useful screen then one can add in patent issues projected growth rate pipeline and balance sheet considerations. Those are a lot of extra variables but I still think the formula is an effective screen and focused on current valuation"
X Link 2024-03-25T17:43Z [----] followers, [---] engagements
"@stock_khoj @semodough They cash in $35m in warrants post-approval want to sign partnership deals ex-USA and should have no trouble either raising cash via a secondary or using non-dilutive funding that is paid back via royalties. Bottom line I'm not worried about their balance sheet"
X Link 2024-03-30T17:22Z [----] followers, [---] engagements
"Bought $ETON past few trading days. [--] consectv Qs of sequential growth - which should con't for next few years at least - and profitable in [----]. Superb EV/revenue ratio clean balance sheet. Niche player in ultra-rare orphan disease w [--] prod on market aiming for [--] by YE25"
X Link 2024-04-02T13:11Z [----] followers, [---] engagements
"@jfais20 @Maximus_Holla Interneuron Pharmaceuticals holding tons into Ph3 binary stroke trial. Was over [--] years ago and still stands out as the worst mistake b/c I had an embarrassingly large % of my entire funds wrapped up in it"
X Link 2024-04-05T19:19Z [----] followers, [---] engagements
"Bought $LYRA. Very bullish on Ph3 trial in pre-surg chronic sinusitis due to report this Q. Ph2 results were signf dose-dep and improved over time. Now Ph3 with best PE N=120 vs. [--] (tx. group/plcb) vs Ph2 of [--] per cell. Has China part balance sheet not an immediate issue"
X Link 2024-04-08T14:03Z [----] followers, [----] engagements
"@AConfidenceGame Yeah but when they be coming to market with their product in best case scenario"
X Link 2024-04-12T16:34Z [----] followers, [---] engagements
"$HROW - sold entire position for moderate profits. Wanted to raise cash company not as undervalued as others I like and unclear if they hit April guideline of delivering a successful manufacturing batch of Triesic"
X Link 2024-04-17T15:50Z [----] followers, [----] engagements
"Current positions in order of size: $CLRB $MIRM $ESPR $ETON $SGMT $CHRS $ANNX (recently sold 20% of $CHRS for minimal loss)"
X Link 2024-04-17T17:04Z [----] followers, [----] engagements
"@arreglalo Sold recently to take long-term capital gains. Hope to buy back in Q4 or so as my long-term view of company hasn't changed. I do think it's now unlikely though that a partner won't sign on until at least NDA acceptance of filing"
X Link 2024-04-17T18:14Z [----] followers, [---] engagements
"$ETON - bought 10% more on Friday an undiscovered/ underfollowed gem IMHO. [--] consecutive quarters of sequential growth will con't for the foreseeable future. Management savvy and disciplined balance sheet not a problem at virtual break-even now solidly profitable in 2025"
X Link 2024-05-13T11:50Z [----] followers, [----] engagements
"$AVTE - bought a 1/2 position on Friday at $19.95 following dip. Ph2b data w novel formulation for PAH due in June. Same/better efficacy much better safety than comp. Obviously bullish on trial - company seamlessly began the Ph3 in Q423 so would think Ph2b results are solid"
X Link 2024-05-13T11:55Z [----] followers, [----] engagements
"$CHRS - sold the last of it my biggest loss in past [--] yrs. Was waiting for last chunk to become a long-term cap loss. No excuses here. They need to continue to clean up the balance sheet and get leaner and more focused as a company should have more clarity in [--] mos"
X Link 2024-05-24T13:45Z [----] followers, [----] engagements
"@JTT20222021 I use a crude metric of: (Market cap + Long-term debt) - cash divided by [----] product revenue (and repeat same for [----] product revenue estimates). I also adjust for projected profitability or burn rate. By that metric I don't see them as cheap"
X Link 2024-06-04T20:02Z [----] followers, [--] engagements
"$ESPR - Love the deal to bring in $300+ million in cash to transform the balance sheet while having royalties revert back after payment cap reached. They "under-promised and over-delovwted""
X Link 2024-06-28T12:44Z [----] followers, [----] engagements
"$ETON - listened to Q2 earnings call remain very bullish. [--] consecutive quarters of revenue growth cash flow positive bigger acquisitions to come this year. Relatively unknown my fave long-term hold"
X Link 2024-08-09T12:45Z [----] followers, [---] engagements
"@Dancingtapas For me the Q3 earnings release will be key. Management has been stating that this is when sales will begin to ramp significantly and I think we'll get the clearest look yet at the balance sheet. Minimal downside from here so I'm still holding all shares"
X Link 2024-08-21T00:51Z [----] followers, [--] engagements
"@jfais20 $IOBT is an immediate multi-bagger if its trial hits its PE at the interim look (likely this Q). $ETON is my fave long-term hold management hinted during CC at big acquisitions coming before YE. $CLRB - want to see Q4 data update as if good partnership/buyout chances go up"
X Link 2024-08-22T12:46Z [----] followers, [----] engagements
"@semodough Yeah I'm also questioning that the data came only from China. $SMMT has a long way to go to get to market"
X Link 2024-09-11T18:12Z [----] followers, [---] engagements
"$SMMT - waiting to see at what level the positive momentum stops. Now at $22 Billion market cap. Wow Is it just me or is it a little premature for $SMMT to have a market cap of $17 Billion w/o having a drug on market until at least [----] Is it just me or is it a little premature for $SMMT to have a market cap of $17 Billion w/o having a drug on market until at least 2006"
X Link 2024-09-13T13:45Z [----] followers, [----] engagements
"$TIL -They're crazy if they don't raise money in the next few days. Nice market cap for a product in Ph1"
X Link 2024-09-13T18:30Z [----] followers, [----] engagements
"@ShoshinValue @HRow $ETON will easily exceed $50m but pace of growth is yoked to new products coming to market thru pipeline or acquisition. Many quarters/years of growth to come and they've hinted at bringing on drugs w higher peak sales potential. I'm just going to enjoy the long-term ride"
X Link 2024-09-14T02:38Z [----] followers, [---] engagements
"@PaulAtreidesBio Bravery or stupidity - hard to tell. Problem is I KNOW the MC is irrational but markets (in a stock or sector) can continue to be irrational. Hopefully investors will sober up over the weekend and we'll see a pullback (soon)"
X Link 2024-09-14T02:40Z [----] followers, [---] engagements
"@wshao8 "business development" - i.e. acquisitions partnering etc. For $ETON it means acquiring additional commercial-stage products. They hinted on Q2 earnings call that a deal or two were in the works and they've previously said their goal is to have [--] products by YE25"
X Link 2024-09-18T20:00Z [----] followers, [--] engagements
"@ShoshinValue I don't see a downside scenario that is realistic or that could readily be anticipated. Perhaps if they ran into regulatory issues that delayed approvals of new drugs or they way over-spend for an acquisition. Neither has happened before though"
X Link 2024-09-19T18:10Z [----] followers, [---] engagements
"Re-bought $SCPH. I think they're now building momentum and hoping for a long steady grind upwards. A long-term hold should see sequential growth for many quarters to come. Quite cheap vs. other micro/small-cap commercialization stage bios"
X Link 2024-09-23T15:13Z [----] followers, [---] engagements
"Biotech thoughts for the day: $ETON con't to make new 52-week highs on strong volume. $ARWR and $URGN con't to droop to near 52-week lows - deservedly IMHO. $ACAD near 52-week lows but interests me at this valuation"
X Link 2024-10-09T14:23Z [----] followers, [----] engagements
"Current holdings in order of size: $ETON $ESPR $SCPH $CELC $ACHV $CADL $ACRV. Stalking: $NAMS $SGMT $VNDA"
X Link 2024-10-11T13:32Z [----] followers, [----] engagements
"$NARI is just 10% off of 5+ multi-year lows. Excellent example of: 1) The difficulty of transitioning to a commercial-stage biotech (shared by so many others). 2) A reminder that innovation does not necessarily lead to proper valuation. Red Sox sent $250K of international money to Yankees in that trade per source. Red Sox sent $250K of international money to Yankees in that trade per source"
X Link 2024-10-11T13:54Z [----] followers, [----] engagements
"@SaicharanAitha I've traded it in the past as well - valuation seems absurd and management is motivated to partner"
X Link 2024-10-16T15:04Z [----] followers, [--] engagements
"$ESPR is up 33% since beginning of month. Bodes well for management delivering on guidance that Q3 would begin the significant ramping up of sales. Like the positive momentum going into Q3 earnings call next month. Still wildly undervalued IMHO"
X Link 2024-10-16T15:07Z [----] followers, [----] engagements
"@monaco_biotech I agree with you. I think it is at least 50/50 that they get a deal done by end of Q125"
X Link 2024-10-17T00:28Z [----] followers, [---] engagements
"@jayabacus Bought some too hope this works out like $SGEN"
X Link 2024-10-18T14:30Z [----] followers, [---] engagements
"@PersimmonTI Follow-up question is a valuation one. $BBIO has a $4.8B market cap and given their $1.7B long-term debt it has an Enterprise Value $6B. Doesn't have enuf cash to reach break-even. Overvalued regardless of PDUFA decision"
X Link 2024-10-21T05:12Z [----] followers, [----] engagements
"@semodough Doug I see $BBIO as overvalued at these levels. About a $6B Enterprise Value and not nearly enough cash to reach break-even. Yes the pipeline is enticing but the valuation is already ahead of itself"
X Link 2024-10-21T05:15Z [----] followers, [---] engagements
"@Ec250940387Ec2 @semodough I don't follow $ALNY so no opinion there"
X Link 2024-10-21T14:27Z [----] followers, [----] engagements
"Bio-twitter is best (for me) for reading contrary points of views of stocks I own. $ANRO joins a few other bios I've owned (e.g. $LYRA $AVTE $RAIN) and made money on but eventually sold before their data blowups. Always useful to re-visit one's positions with skepticism"
X Link 2024-10-23T13:28Z [----] followers, [----] engagements
"$VKTX - bought some for a swing trade with upcoming data update. Have questions about its valuation but not about the quality of its data"
X Link 2024-10-23T15:26Z [----] followers, [----] engagements
"Sold $VKTX. I'm happy with a 20% 1-day gain. Might re-buy if it re-traces significantly before data release. $VKTX - bought some for a swing trade with upcoming data update. Have questions about its valuation but not about the quality of its data. $VKTX - bought some for a swing trade with upcoming data update. Have questions about its valuation but not about the quality of its data"
X Link 2024-10-24T14:56Z [----] followers, [----] engagements
"Bought $VNDA past [--] days. Problematic management Yes. Tremendously undervalued Yes. Correct to shut down low-ball buyout offers Yes. Negative EV despite having plenty of cash to get to profitability Yes"
X Link 2024-10-25T13:04Z [----] followers, [----] engagements
"Re-bought $VKTX for short-term swing trade $71. In a gambling mood with Breeder's Cup weekend coming up"
X Link 2024-10-31T15:28Z [----] followers, [----] engagements
"$VKTX - sold $73 to exit w some profits to now bet freely on Breeder's Cup races today and tomorrow. Per $VKTX you never know how "the street" perceives results so I am happy to just take trading profits for the 2nd time. Too I don't think they're undervalued at this stage. Re-bought $VKTX for short-term swing trade $71. In a gambling mood with Breeder's Cup weekend coming up. Re-bought $VKTX for short-term swing trade $71. In a gambling mood with Breeder's Cup weekend coming up"
X Link 2024-11-01T13:39Z [----] followers, [----] engagements
"$VKTX: Kind of what I expected - excellent data muted market reaction. Now the issue is when is the next significant catalyst Next significant data release"
X Link 2024-11-04T14:58Z [----] followers, [----] engagements
"$VKTX - couldn't resist re-buying at $70. Expect momentum to pick up this week"
X Link 2024-11-04T15:16Z [----] followers, [----] engagements
"Bought $CRVO past [--] days at $12.34. Am bullish on Ph2b trial in DLB with data due next month. Very binary event. Given low daily volume and a MC of only $106m the potential upside is enormous. I welcome bearish POVs"
X Link 2024-11-07T13:51Z [----] followers, [----] engagements
"$VNDA - sold position for about 14% 2-week profit. My opinion on company hasn't changed just having a very good year personally and I like selling into (market strength). Will be stalking stock for re-entry anytime before Q4 earnings call"
X Link 2024-11-07T16:42Z [----] followers, [---] engagements
"@mathcoredad Well I'm rooting for you but you know things aren't looking good when analyst downgrades follow the earnings release CC. I held it for several months and b/c I added when it was $1.70 actually eked out a profit overall in $ESPR this year. However I am now "unfollowing" it"
X Link 2024-11-08T05:42Z [----] followers, [---] engagements
"$VKTX - sold for penny profits this last time. I'm among those who think the upcoming major "catalyst desert" will work against them and I don't consider them undervalued given that they are years from market"
X Link 2024-11-08T14:49Z [----] followers, [---] engagements
"Re-bought $PRTA at $17.50 past few days after selling at $23 in March. Lots of shots on goal w multiple data sets coming this Q and next. Multiple meaty corporate partnerships. Really like the R/R here"
X Link 2024-11-11T15:01Z [----] followers, [----] engagements
"$VKTX: Rebought $59 for a possible short-term swing trade after selling at $70 [--] trading days ago"
X Link 2024-11-12T16:02Z [----] followers, [----] engagements
"@buylowersellhih @ChrisOlin I'd look at their October slide deck then listen to the [--] minute Earnings Call today. You'll learn what you need to know. I was very encouraged by the Call will tweet about it Monday pre-market"
X Link 2024-11-13T02:48Z [----] followers, [--] engagements
"$ETON - great earnings call company executing flawlessly. Interesting tidbit was management said a goal was to attain a $1B market cap - i.e. 4x current price. 💪💪"
X Link 2024-11-13T14:15Z [----] followers, [---] engagements
"@ChrisOlin Let's wait for their Q3 earnings call/letter to shareholders and see what we learn"
X Link 2024-11-13T14:17Z [----] followers, [--] engagements
"Sold $VKTX yesterday for day-trading profits. Have a feeling stock is going to get close to $50 if biotech market takes a breather. Never like it when stock is red on a green market day. $VKTX: Rebought $59 for a possible short-term swing trade after selling at $70 [--] trading days ago. $VKTX: Rebought $59 for a possible short-term swing trade after selling at $70 [--] trading days ago"
X Link 2024-11-13T14:46Z [----] followers, [----] engagements
"Shorted $RNA again this time at $51. (Had covered a short profitably at $47 last month.) A $6.1B market cap for a company at least 2-3 years away from marketing their 1st drug seems excessive to me"
X Link 2024-11-13T15:04Z [----] followers, [----] engagements
"@rddbryant @buylowersellhih @ChrisOlin Yes I thought it was an excellent call as well and was pleasantly surprised that CEO mentioned the $1B market cap goal"
X Link 2024-11-13T15:59Z [----] followers, [--] engagements
"@buylowersellhih Just lets investors know that management feels they're still in early stages of their growth (which they explicitly stated). Also implies that they wouldn't entertain buyout offers that valued them at a significantly lower market cap"
X Link 2024-11-13T16:44Z [----] followers, [--] engagements
"$CELC: Re-bought yesterday. After re-reviewing the data and listening to earnings call am increasingly bullish on Ph3 trial readouts in 1H25 and 2H25. Not a swing trade (barring a huge run up) will hold thru data"
X Link 2024-11-15T13:43Z [----] followers, [---] engagements
"$SCPH: Sold all yesterday for moderate loss (for 2nd time). Going forward I think I need to stick with commercialization-stage bios that are either profitable or have multiple products on market"
X Link 2024-11-15T13:50Z [----] followers, [---] engagements
"$BBIO - this will be interesting market cap at $5.6B w $1.7B of LTD might burn through cash ($549) in [--] year. That is almost an EV of $7B with 1st product soon to be on market. Hard to think it's undervalued but not getting in the way of its positive momentum"
X Link 2024-11-25T14:42Z [----] followers, [----] engagements
"@tonyboloj I have no knowledge of the drug. However management has executed flawlessly so I'm going to assume it's a solid acquisition. Current sales force can detail it. On the way to a $1B market cap"
X Link 2024-11-25T22:26Z [----] followers, [--] engagements
"$ARWR - bought at $23 after deal news today. Amazing to me that stock is still closer to 52-week lows than highs. Haven't seen a non-buyout deal of this magnitude in"
X Link 2024-11-26T15:10Z [----] followers, [----] engagements
"$AXSM - why did so many patients in the narcolepsy study decline to participate in the 6-month OLE"
X Link 2024-11-26T16:54Z [----] followers, [----] engagements
"Bought $CGEM yesterday full position. A long-term hold as next data sets are a few Qs in the future. Super cheap in my view pristine balance sheet. Excited to see where things stand a year from now"
X Link 2024-12-04T14:19Z [----] followers, [---] engagements
"Sold $STRO and $ARWR for minor profits. I remain bullish on both just liked others better wanted to raise cash and "keep (more) powder dry" in case of downturn. Too neither has near-term major catalysts"
X Link 2024-12-04T16:50Z [----] followers, [----] engagements
"$CRVO volatility has been quite intense past few weeks even for micro/small-cap biotechs. Binary Ph2b data in early DLB coming this month. At least somebody else is hopeful that good results are coming given this morning's action"
X Link 2024-12-06T15:44Z [----] followers, [----] engagements
"$CMRX - Gobbled up some at the open. Expect it to really move up as news gets out. Filing for AA YE w lead drug addressing a $750m market. a $4 stock price = $360m with $152m in cash and a PRV voucher. Yes they owe milestones & royalties but stock is now dirt cheap"
X Link 2024-12-10T14:39Z [----] followers, 10.5K engagements
"$CMRX - Bought 33% more soon after the open now my #2 position ($ETON is #1). Cost basis now $2.29. If company executes as planned I still believe it's significantly undervalued. Expect another boost up if they do indeed file for AA by YE"
X Link 2024-12-11T17:49Z [----] followers, [---] engagements
"$CMRX - Listened to CC about filing for AA. Impressed by management have increased confidence in company's prospects. Expect stock to be a multi- bagger at this level within [--] years. #2nd biggest position for me a l-t hold "
X Link 2024-12-12T14:02Z [----] followers, [----] engagements
"$KURA - With a market cap of $750m hard to believe it is now trading below cash levels (of $785m)- and they're in line to receive $420m in milestones in the next [--] quarters from their deal w KK. Welcome to biotech investing"
X Link 2024-12-12T19:16Z [----] followers, [----] engagements
"@monaco_biotech $ETON is going to grind forward and I'm betting on them that they accomplish their longer-term goal of achieving a $1B market cap - roughly a triple from here. Fun to watch them execute"
X Link 2024-12-17T15:03Z [----] followers, [---] engagements
"Re-bought $VKTX at $42.4 after selling at $51 two weeks ago. I've never owned them b/c I expect a buyout so today's (irrational) reaction to $MRK news seems like a decent buying/trading opportunity. Valuation is now much more reasonable"
X Link 2024-12-18T14:49Z [----] followers, [----] engagements
"@Berlinergy $CMRX - My long-term price target is $12 which at current shares outstanding translates to a $1B market cap"
X Link 2024-12-19T17:53Z [----] followers, [---] engagements
"$KURA now selling at a negative Enterprise Value of almost $100m. Irrational but such is life in biotech-land. Biotech indices now flat or negative for [----]. $KURA - With a market cap of $750m hard to believe it is now trading below cash levels (of $785m)- and they're in line to receive $420m in milestones in the next [--] quarters from their deal w KK. Welcome to biotech investing. $KURA - With a market cap of $750m hard to believe it is now trading below cash levels (of $785m)- and they're in line to receive $420m in milestones in the next [--] quarters from their deal w KK. Welcome to biotech"
X Link 2024-12-19T17:59Z [----] followers, [----] engagements
"@ValueDig $AGIO $KURA $SNDX $VNDA"
X Link 2024-12-20T17:38Z [----] followers, [---] engagements
"$ARWR - re-bought 50% position $19.50. Waiting to see if it goes (much) lower before buying full position. Had sold it profitably a month ago at $24 so the discount at today's price seems like a gift. Anyone else finding $ARWR interesting at $20. Lots of intriguing valuations now in micro/small-cap bios. Anyone else finding $ARWR interesting at $20. Lots of intriguing valuations now in micro/small-cap bios"
X Link 2024-12-20T18:44Z [----] followers, [----] engagements
"Sold $VKTX again for minor trading profits. Just wanted to raise cash and like others better given what I consider their "catalyst desert" for the time being. As much as I like their data other companies have had plenty of time to consider/partner so not expecting it soon. Re-bought $VKTX at $42.4 after selling at $51 two weeks ago. I've never owned them b/c I expect a buyout so today's (irrational) reaction to $MRK news seems like a decent buying/trading opportunity. Valuation is now much more reasonable. Re-bought $VKTX at $42.4 after selling at $51 two weeks ago. I've never owned them b/c"
X Link 2024-12-20T18:48Z [----] followers, [----] engagements
"$CMRX valuation is still super cheap IMHO. Today's extended credit line - untapped as yet - and potentials proceeds from a PRV put them in enviable position to launch 1st to market drug likely in Q3. Remains my #2 position and a long-term hold"
X Link 2024-12-30T14:59Z [----] followers, [----] engagements
"$SNDX - bought more this morning. I think 1st to market mover advantage with mono tx. sub-group AML drug and likely 1st to market with combo regimens is the "catbird's seat". And launch of GvHD drug (note RoyPharm deal) seems largely ignored"
X Link 2024-12-30T15:04Z [----] followers, [----] engagements
"@Nick09321587504 @JNap5C They will both release data and communicate how they plan to progress the drug (and the trials they run) going forward"
X Link 2024-12-30T19:39Z [----] followers, [--] engagements
"2024 Biggest Wins: $ETON $CADL $XERS $CMRX $ACHV $CELC $VKTX [----] Biggest Losses: $CHRS $FULC $SCPH [----] Stats: Last [--] yrs. (Avg.) Me: + 47.2% + 30.3% XBI: + 0.9% + 05.4% NBI: - 1.4% + 05.7% RUT: + 10.0% + 06.4% S&P500: + 23.3% + 12.8% NASD: + 28.6% + 17.3% [----] Stats: Last [--] yrs. (Avg.) Me: + 47.2% + 30.3% XBI: + 0.9% + 05.4% NBI: - 1.4% + 05.7% RUT: + 10.0% + 06.4% S&P500: + 23.3% + 12.8% NASD: + 28.6% + 17.3%"
X Link 2025-01-02T12:13Z [----] followers, [----] engagements
"Congrats to $NARI longs. Per usual it's crucial to "Buy low and Sell high" as stock was well over $100 [--] years ago with dips below $40 in past [--] months. Hoping that buyout is a good omen for overall Biotech market"
X Link 2025-01-07T14:09Z [----] followers, [---] engagements
"@intimepk I think like any competent management team they will be open to all options (e.g. partner buyout or go it alone.) Personally I'd be surprised if they did try to completely commercialize it on their own"
X Link 2025-01-07T17:56Z [----] followers, [---] engagements
"$ZNTL - Bought 20% more. Like the Investor Day announcement - pre-market on a Wed. - that will have lots of new data and presumably a clear future direction. With lots of cash and a huge negative EV love the risk/reward here"
X Link 2025-01-10T15:16Z [----] followers, [----] engagements
"Some interesting names - some really solid micro/smid-cap biotechs - hitting 52-week lows: $ACHV $AVDL $CELC $DAWN $ETNB $GPCR $IOVA $KURA $URGN"
X Link 2025-01-10T17:05Z [----] followers, [----] engagements
"I hope this trend of every biotech feeling compelled to release (mostly) non-newsworthy PRs on the first morning of JPM dies a quick death"
X Link 2025-01-13T14:12Z [----] followers, [---] engagements
"$VKTX (No Position): Seems dead in the water until we get (closer to) new data from a new trial. Prospective partners have had lots of time to review existing data - and they're clearly not biting. Too short duration Ph2 oral might not move the needle much"
X Link 2025-01-15T16:33Z [----] followers, [----] engagements
"$ZNTL: Not often you see a biotech with an Enterprise Value of negative $200m. A lot of recent volatility in the stock price even for small-cap biotech land. Hope to get a clear direction from management on Jan. 29th - incl. steps taken to reduce burn rate"
X Link 2025-01-16T19:42Z [----] followers, [----] engagements
"$VKTX - When you look at valuations for $ALT $ETNB $GPCR $SGMT you realize that $VKTX could fall a lot more. Not saying all [--] companies should be valued similarly but none have an Enterprise Value of even $800m while $VKTX's current EV = $2.7B"
X Link 2025-01-16T19:46Z [----] followers, [----] engagements
"@BioValues I am clueless. Remember for every seller there is a buyer. My assumption is the volatility has no meaning. I say that because I think of all the bios that traded down sharply 1-2 days prior to a significantly positive data release (and one recognized as such by the market)"
X Link 2025-01-16T20:37Z [----] followers, [---] engagements
"$PRTA - bought 60% position last wk in low $13s hope to buy rest this wk at close to same price. Am bullish on SPA Ph3 in AL Amlydss - data due Q225 as well as potential of Ph012 in Alzhm to have strong data mid-year. Have [--] big Pharma deals for [--] lead drugs EV only $220m"
X Link 2025-01-21T15:06Z [----] followers, [----] engagements
"Bought 60% position in $TARA past few days. EV is $0 company has Q2 data readouts in bladder cancer and lymphatic malformations with strong prior data. Ph3 data in IV choline chloride due YE25/Q126 offers great potential value too. Has enough cash to get to 2027"
X Link 2025-01-28T13:39Z [----] followers, [----] engagements
"$PRTA - bought more to get to a "100%/typical-sized position". I like to buy on "Red" days. Will definitely be holding through Ph3 data readout in Q2. $PRTA - bought 60% position last wk in low $13s hope to buy rest this wk at close to same price. Am bullish on SPA Ph3 in AL Amlydss - data due Q225 as well as potential of Ph012 in Alzhm to have strong data mid-year. Have [--] big Pharma deals for [--] lead drugs EV only $220m. $PRTA - bought 60% position last wk in low $13s hope to buy rest this wk at close to same price. Am bullish on SPA Ph3 in AL Amlydss - data due Q225 as well as potential of"
X Link 2025-02-03T14:55Z [----] followers, [----] engagements
"$IMCR - bought yesterday @ $30. Like the r/r here - esp. limited downside IMHO. While not my reason for buying I do see them as ideal candidate for a buyout as they own w/w rights to lead drug w nice sales (Q3=$80m) & true "pipeline in a product". Ph1 HIV data this Q a bonus"
X Link 2025-02-07T12:31Z [----] followers, [----] engagements
"$CMRX - ditto [--] weeks later. Nice move today especially in the face of strong "red" day for biotech. $CMRX (my #2 holding) also making new 52-week highs on strong volume. Awaiting FDA acceptance this Q of filing for lead glioma drug with a launch & PRV in 2H25. Stock still quite cheap IMHO esp. with potential of Ph3 trials in 1L and 2nd-Gen prod that will read out Q3/Q2. $CMRX (my #2 holding) also making new 52-week highs on strong volume. Awaiting FDA acceptance this Q of filing for lead glioma drug with a launch & PRV in 2H25. Stock still quite cheap IMHO esp. with potential of Ph3 trials"
X Link 2025-02-07T17:42Z [----] followers, [----] engagements
"$CELC: Re-bought full position ahead of pivotal Q2 data. Have traded profitably before but now planning to hold thru data"
X Link 2025-02-10T14:44Z [----] followers, [----] engagements
"$CMRX - have a feeling below quote will be true again today with receipt of Priority Review Aug. PDUFA w no need for AdComm. If 1L trial is successful then stock will easily hit double digits. $CMRX (my #2 holding) also making new 52-week highs on strong volume. Awaiting FDA acceptance this Q of filing for lead glioma drug with a launch & PRV in 2H25. Stock still quite cheap IMHO esp. with potential of Ph3 trials in 1L and 2nd-Gen prod that will read out Q3/Q2. $CMRX (my #2 holding) also making new 52-week highs on strong volume. Awaiting FDA acceptance this Q of filing for lead glioma drug"
X Link 2025-02-18T13:41Z [----] followers, [----] engagements
"@Biohazard3737 When is the last time a nano/micro/smid-cap biotech reacted well to a partnering deal $STOK joins recent list of declining price post-partnering news that includes $ARWR $KURA"
X Link 2025-02-21T04:44Z [----] followers, [----] engagements
"$LRMR - bought 90% of a full position. Company trading at cash bullish on strong dose-dependent data to date for lead (only) drug with data updates coming mid-year"
X Link 2025-02-24T15:07Z [----] followers, [----] engagements
"$DAWN - I don't see it as undervalued. EV/prod revenue projection for [----] = [---]. Got way ahead of itself when trading in high teens. Hopefully a growth story for years but seems fairly valued now"
X Link 2025-02-26T20:29Z [----] followers, [----] engagements
"@niubi1988 No longer follow $CRNX (b/c I thought it was so overvalued) so hard to say. $DAWN probably a safer bet though"
X Link 2025-02-27T15:15Z [----] followers, [---] engagements
"Red days are for buying Re-bought half position in $ARWR (at 10%+ discount from last time I sold it). I'd prefer to patiently hold it long-term because the company has so many "ways to win". We shall see. Current positions in order of size: $ETON $CMRX $PTGX $URGN $LRMR $TARA $CELC $ACHV Considering for next Buys: $ARWR $CGEM $DERM $GPCR $HRMY $PRTA $RCKT Current positions in order of size: $ETON $CMRX $PTGX $URGN $LRMR $TARA $CELC $ACHV Considering for next Buys: $ARWR $CGEM $DERM $GPCR $HRMY $PRTA $RCKT"
X Link 2025-03-03T15:10Z [----] followers, [----] engagements
"$CMRX - pretty impressive that it continues to make new 52-week highs given desultory overall biotech sector performance of late. Con't to believe that stock still has a lot of upside with multiple catalysts Q2/Q3"
X Link 2025-03-03T16:37Z [----] followers, [----] engagements
"$PTGX - Home run Ph3 PV data. Am more confident that Ph3 psoriasis data in Q2 will be good. Silly to sell this on a red day for biotech. Expecting a move up to mid-40s soon. See Ph2b UC trial as most iffy but w higher upside impact if good data than downside risk w failure"
X Link 2025-03-03T17:40Z [----] followers, [---] engagements
"Screw it - bought more $ARWR now at full-sized position with entry at avg. of $18"
X Link 2025-03-03T20:24Z [----] followers, [----] engagements
"Swapped $PTGX for $PRTA view the latter as more undervalued. Still very bullish on former in general but least excited by data readout in UC this Q. $PRTA with SPA Ph3 data in Q2 w upside bonus of Ph1 Alz data mid-25"
X Link 2025-03-04T15:00Z [----] followers, [----] engagements
"$ALT $GPCR $SGMT $VKTX - [--] sisters all dressed up at the big obesity/MASH gala and nobody is asking them to dance"
X Link 2025-03-04T15:33Z [----] followers, [---] engagements
"$TCMD: Bought full position yesterday. Boring growth story company profitable enuf cash to fund share buyback. EV/product revenue is less than [---] so super cheap IMHO. Nice way to diversify from trial outcome-driven bios"
X Link 2025-03-06T14:14Z [----] followers, [----] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing